



Cite this: *Chem. Soc. Rev.*, 2024,
53, 11725

Recent advances in peptide macrocyclization strategies

Pengyuan Fang,^a Wing-Ka Pang,^b Shouhu Xuan,^c Wai-Lun Chan^c *^{ad} and Ken Cham-Fai Leung *^b

Recently, owing to their special spatial structures, peptide-based macrocycles have shown tremendous promise and aroused great interest in multidisciplinary research ranging from potent antibiotics against resistant strains to functional biomaterials with novel properties. Besides traditional monocyclic peptides, many fascinating polycyclic and remarkable higher-order cyclic, spherical and cylindric peptidic systems have come into the limelight owing to breakthroughs in various chemical (e.g., native chemical ligation and transition metal catalysis), biological (e.g., post-translational enzymatic modification and genetic code reprogramming), and supramolecular (e.g., mechanically interlocked, metal-directed folding and self-assembly *via* noncovalent interactions) macrocyclization strategies developed in recent decades. In this tutorial review, diverse state-of-the-art macrocyclization methodologies and techniques for peptides and peptidomimetics are surveyed and discussed, with insights into their practical advantages and intrinsic limitations. Finally, the synthetic-technical aspects, current unresolved challenges, and outlook of this field are discussed.

Received 21st April 2024

DOI: 10.1039/d3cs01066j

rsc.li/chem-soc-rev

Key learning points

- (1) Macro cyclic peptides and their derivatives demonstrating different structures and diverse functionalities have become multidisciplinary research megatrends across chemistry, biomedicine, and materials science.
- (2) Their *de novo* design, efficient synthesis and precision modification have always been highly challenging but desirable in both academic and industrial settings.
- (3) Various new macrocyclization strategies for peptides and peptidomimetics have been developed over the recent decades *via* chemical, biological and supramolecular approaches.
- (4) Long-standing challenges in macrocyclic peptide synthesis in terms of scope, selectivity, sustainability, and scalability leave much room for further exploration and advancements.

1. Introduction

Between 1899 and 1908, Emil Fischer (Nobel Prize winner in Chemistry 1902) investigated proteins and first proposed the concept of a “peptide bond”, which preluded and emblematized humankind’s odyssey through the vibrant and dynamic

research area of “peptide science”. In 1959, Robert Bruce Merrifield (Nobel Prize winner in Chemistry 1984) pioneered solid-phase peptide synthesis (SPPS), a revolutionary breakthrough in the production of synthetic peptides, which is now a well-established common practice in peptide-based drug discovery and development in both academic and industrial settings. Owing to the efforts of scientists in this field globally, since the beginning of the 21st century, there have been many new peptides documented due to serendipitous discoveries from nature, tailored/*de novo* designs inspired by nature, or just simply curiosity-driven pursuit by humans. It is with such an immensely diverse pool of new peptides of unprecedented forms and functions, as well as the inexhaustible creativities and unlimited perseverance of humankind, that peptide science transcends the traditional knowledge boundaries of organic chemistry and biochemistry, becoming deeply

^aJoint School of National University of Singapore and Tianjin University, International Campus of Tianjin University, Binhai New City, Fuzhou 350207, Fujian, P. R. China. E-mail: kwlchan@nus.edu.sg

^bDepartment of Chemistry, Hong Kong Baptist University, Kowloon Tong, Kowloon, Hong Kong SAR, P. R. China. E-mail: c fleung@hkbu.edu.hk

^cCAS Key Laboratory of Mechanical Behavior and Design of Materials, Department of Modern Mechanics, University of Science and Technology of China, Hefei, Anhui 230027, P. R. China

^dDepartment of Chemistry, National University of Singapore, 3 Science Drive 3, Singapore 117543, Singapore

integrated with medicinal chemistry, chemical biology, synthetic biology, inorganic chemistry, supramolecular chemistry, materials science, biomedical science, food science, cosmetic science, and even computational science (Fig. 1).

Peptides are essential components in living organisms and exist as hormones, neurotransmitters, growth factors, and ion channel receptors to, for instance, regulate various physiological activities.¹ They have molecular weights between those of small organic molecules and proteins (usually composed of 2–50 amino acids) and are special substances that can be facilely synthesized and modified. Peptide-based drugs are usually favorably endowed with high bioactivity, high specificity, and low toxicity, which surpass small-molecule drugs.^{2,3}



Pengyuan Fang

Pengyuan Fang obtained his Bachelor's degree in Applied Chemistry from Zhengzhou University of Light Industry in 2022. He is currently pursuing his Master's degree in Materials Engineering through the joint program of Fuzhou University and Tianjin University under the guidance of Prof. Yixin Lu and Dr Wai-Lun Chan at the Joint School of National University of Singapore and Tianjin University.

Furthermore, because of their unique spatial configuration, peptides are ideal modalities to modulate protein–protein interactions (PPIs).⁴ This has aroused a great deal of interest in the medicinal chemistry of therapeutic peptides. In contrast to the intrinsic metabolic instability of linear peptides,⁵ the constrained flexibility of their cyclic counterparts results in much higher resistance to proteolytic enzymes, with their more rigid conformation manifesting much better specificity when interacting with protein targets.^{6,7} In addition, the specific, fixed conformation of cyclic peptides reduces the entropic cost of binding to receptors, and thus increases the binding affinity.^{7,8} According to the “chameleon hypothesis”, cyclic peptides exhibiting smart conformational dynamics (*i.e.*,



Wing-Ka Pang

Wing-Ka Pang obtained his B.Sc. (Hons.) degree in Chemistry from Hong Kong Baptist University and is currently a postgraduate student under the supervision of Professor Ken Cham-Fai Leung in the Department of Chemistry, Hong Kong Baptist University.



Shouhu Xuan

Shouhu Xuan was born in Hefei, Anhui, China. He received his B.Sc. degree in Chemistry from Anhui Normal University and PhD degree in Inorganic Chemistry from The University of Science and Technology of China. He worked as a Postdoctoral Fellow at The Chinese University of Hong Kong. He is currently a Professor in the Department of Modern Mechanics, University of Science and Technology of China. His

research interests are soft materials, wearable electronic fabrics and intelligent anti-impact materials.



Wai-Lun Chan

Wai-Lun Chan received his BSc (Hons.) in Chemistry (2014) and a MA in Communication (2015) from Hong Kong Baptist University, followed by a PhD in Chemistry (2019) from the National University of Singapore under the supervision of Prof. Yixin Lu. After a postdoctoral visit (2020) with Prof. Markus Zweckstetter at the German Center for Neurodegenerative Diseases and Max Planck Institute for Biophysical

Chemistry, he was appointed as a Research Assistant Professor (2021) with Prof. Wing-Tak Wong at the Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, and then a Research Associate Professor (2023) with Prof. Yixin Lu at the Advanced Manufacturing Centre, Joint School of National University of Singapore and Tianjin University. His current research interests include asymmetric organocatalysis, natural product synthesis, biomolecule modification, and targeted molecular imaging and phototherapy against cancer and neurodegeneration.






Fig. 1 Selected historical development of peptide science.

shielding or exposing their polar functionalities in response to the environment) are found to possess enhanced cell membrane permeability due to their transiently reduced surface polarity and area.^{6,7,9}

In essence, many bioactive natural products are cyclic peptides, such as cyclopeptide alkaloids and cyclotides, with most of them being cyclized precisely through the formation of lactam, lactone, or in the form of disulfide bonds.¹⁰ However, this seemingly simple way of ring creation in nature is rather difficult to accomplish by purely traditional chemical means. Firstly, peptide macrocyclization is an entropy-unfavorable

process, where intermolecular oligomerization reactions always compete with intramolecular ring-closing reactions; therefore, it must be carried out under either high-dilution conditions or compartmentalization.¹¹ Secondly, the imperfect chemo/stereo/site-selectivity at the points of cyclization, as well as inevitable epimerization of the product due to strong acids/bases or reagents will adversely affect the purity, and hence the bioactivities of cyclic peptides.¹² Due to contemporary advances in various novel and efficient macrocyclization strategies and techniques,⁴ not only the above-mentioned naturally occurring cyclopeptides can be synthesized, but also more structurally complex variants, with the introduction of unnatural amino acids and other non-peptide components, can be accessed with unparalleled properties. Thus, currently, the strategic designs and efficient preparation of macrocyclic peptides and peptidomimetics have become key research hotspots and megatrends in both academia and industry.

Given the multidisciplinary nature of this topic, large knowledge gaps exist for the researchers from different backgrounds (e.g., chemists, biologists, and materials scientists). Thus, in this tutorial review, we aim to provide a panoramic view of the whole research landscape and a reader-friendly, up-to-date catalogue for the synthetic breakthroughs over the recent decades (Fig. 2). In general, peptide macrocyclization strategies can be categorized into three approaches, as follows: (a) chemical, both non-catalytic and catalytic, (b) biological, and (c) supramolecular approaches. Non-catalytic chemical methods include chemoselective ligation, nucleophilic (aromatic) substitution, (cyclo)addition, condensation, and multicomponent reactions between unnatural moieties/external components and amino acid residues; metal-catalyzed chemical methods include carbon–carbon/heteroatom bond formation *via* click, cross-coupling, C–H activation and olefin metathesis reactions, in addition to a few cases of photochemical examples. These distinctive, diverse chemical approaches, together with the underlying chemical principles, are the focal point of this tutorial. Examples are selected based on their novelty (e.g., new chemistry with reagents/reactions/protocols, compatibility



Ken Cham-Fai Leung

Academy of Sciences and named as a Fellow of the International Association of Advanced Materials (FIAAM, Sweden). He gained both his B.Sc. and PhD degrees in Chemistry from The Chinese University of Hong Kong, and then conducted three-year postdoctoral research with Professor Sir Fraser Stoddart at The California NanoSystems Institute and Department of Chemistry and Biochemistry, The University of California at Los Angeles, USA. His research interests are in the fields of nanomaterials chemistry, supramolecular polymer materials, catalysis, sensors, and nanomedicine.






Fig. 2 Contemporary synthetic strategies for different categories of peptidic macrocycles.

and orthogonality, and creation of new rigid/flexible linkages or functionalities), selectivity (*e.g.*, workable on specific moieties and amino acid residues) and practicality (*e.g.*, reaction cleanliness and efficiency, *i.e.*, yield and rate, and operation and subsequent purification simplicity), where they can offer potential novel strategic solutions or alternatives to current macrocyclic peptide synthetic challenges compared with well-established or well-known methods to satisfy new and future demands.

Owing to the continuous quantum leap in advanced genetic engineering (*e.g.*, genetic code reprogramming) and enzyme engineering (*e.g.*, directed evolution and post-translational enzymatic editing), biosynthetic approaches have recently gained increasing momentum and popularity. From a supramolecular chemistry perspective, many higher-order cyclic peptide-based nano-structures can be obtained by mechanical interlocking and metal/noncovalent interaction-directed self-assembly. Nevertheless, given that they are beyond the scope of this tutorial, the biological and supramolecular approaches are only briefly introduced herein.

Finally, the outstanding features, advantages and limitations of each strategy are highlighted and analyzed, and the general synthetic-technical aspects (*e.g.*, liquid/solid-PPS), and unresolved challenges (*e.g.*, scope, chemo/stereo/site-selectivity, conformational control/stability, sustainability, and scalability) are highlighted and discussed, and subsequently we share our insights into the outlook of this field. We hope that a large multidisciplinary audience can quickly grasp the details and trends in macrocyclic peptide research, thereby contributing to and benefiting from this fundamental applied science and technology for the future betterment of humankind.

2. Non-catalytic chemical macrocyclization strategies

The most common macrocyclization of peptides can be achieved *via* the straightforward condensation of their terminal amino and carboxyl groups (lactamization). In addition, the thiol group of the cysteine sidechain has inherent nucleophilicity to react with electrophiles; the 1,2 aminothiol moiety of N-terminal cysteine also plays a bifunctional role to undergo different acyl transfers; and the amino group of the terminal sidechain of lysine can be easily subjected to aldehyde condensation to form active imine structures. All these have been reported for the ring formation reactions of peptides. In brief, non-catalytic chemical approaches are largely dependent on the typical functional group transformations of the natural amino acid residues. These methods are usually smartly and carefully designed and performed under relatively optimally mild conditions, with good selectivity and tolerance to other amino acid side chains in most cases.

2.1. Ligation-mediated intramolecular cyclization

Direct macrocyclization in the form of amide linkage is the simplest way to synthesize cyclic peptides. However, this amide bond formation usually suffers from very poor chemical selectivity, resulting in isomerization and oligomerization problems. Thus, to circumvent these disadvantages, most amide-connected macrocyclic peptides require the installation of auxiliary groups, the modification of terminal groups, or the mediation of coupling agents. In this regard, native chemical ligation reactions have emerged as a powerful routine strategy for peptide elongation and protein synthesis, and importantly, peptide macrocyclization.




2.1.1. Native chemical ligation-mediated cyclization. In 1994, Kent and coworkers developed a mild, site-selective reaction to link two unprotected peptide fragments, which is currently called native chemical ligation (NCL).¹⁰ The discovery of NCL was inspired by thioester bioorganic chemistry, *i.e.*, *S*-acetyl coenzyme A, with more than 50 years of intense multidisciplinary research endeavors worldwide.¹³ In this reaction, the thioester is first installed at the C-terminus of the peptide *via* solid-phase peptide synthesis (SPPS), and then reversibly transesterified with the N-terminal cysteine of another peptide in pH-neutral aqueous solution, followed by irreversible *S*-to-*N* acyl transfer between the thioester and the terminal amino groups to complete the conjugation of the two peptides. The good chemical selectivity of this reaction originates from the intrinsic nucleophilicity of cysteine in a pH-neutral aqueous environment, as well as the reversibility of the transesterification step. At pH = 7, besides cysteine, all the other amino acid side chains become less nucleophilic; therefore, only the thiol sidechain of cysteine can dominantly trans-esterify with the C-terminal thioester, while other side chains remain “silent”. Besides, the *S*-to-*N* acyl transfer of the thiol group cannot occur without the presence of an adjacent amino group originating from the N-terminus. This NCL protocol was successfully extended to the cyclization of cysteine-rich peptides by Tam and coworkers in 1997¹¹ (Scheme 1a). The thiol group of the final cyclic peptide product could be easily oxidized to form intramolecular disulfide bonds for further folding and locking structures. This zip-like peptide cyclization assisted by such thiolactone exchange is otherwise known as the thia-zip reaction.¹²

The development of the NCL strategy and its extended methods was groundbreaking in the field of cyclic peptide synthesis. Presently, application-wise, NCL methods have progressed substantially in various aspects. For example, solid-phase resins have been employed for the pseudo-dilution effect, which can greatly suppress the side-oligomerization of peptide chains and promote the sought-

after intramolecular cyclization.^{14–16} The incorporation of unnatural amino acids/moieties containing thiols, as well as the application of their desulfurization has also increased the number of reaction sites on peptides, where NCL and other addition reactions can take place beyond cysteines.^{17,18} Selenocysteine-based NCL can accelerate the rate of the ligation reaction and minimize side-reactions, such as thioester hydrolysis. The seleno-alcohol group can be further treated by alkylation, oxidation, and reduction, which is very helpful for the further derivatization and functionalization of the resulting cyclic peptides.^{19,20} NCL is a powerful and practical cyclization method with good chemoselectivity, which is appropriate for the preparation of cyclic peptides of various sizes and folding and integrating with continuous-flow and microfluidic technologies.²¹

Currently, NCL macrocyclization methods are one of the most commonly used strategies and most likely strategies to be translated to industrial production. This is because they showcase a few advantages, as follows: (i) simple preparation of linear peptide precursors and simple operation of the reaction; (ii) no epimerization or racemization of the cyclic peptide products or at the site of ligation; (iii) high water compatibility at neutral pH; and (iv) high reaction specificity in the presence of other internal cysteines, and other unprotected amino acids would not affect the reaction. However, their limitations are also conspicuous, as follows: (i) the presence of a C-terminal thioester and N-terminal cysteine is a required (although the auxiliary-mediated ligation strategy is available) and (ii) only in the case of peptide ring formation, without possibility for further functionalization or addition of new moieties for conformational control. Accordingly, various novel peptide macrocyclization strategies have been developed in the recent decade around the world, as shown herein, to complement and surpass NCL.

2.1.2. Staudinger ligation-mediated cyclization. In 2008, Kleineweischede and Hackenberger first demonstrated that the scaffold-free Staudinger ligation can be used for cyclic




Scheme 1 Selected representative ligation-mediated peptide macrocyclization strategies. (a) 1,2-Aminothiol and thioester ligation (native chemical ligation, NCL) and (b) azide and phosphine-linked thioester Staudinger ligation.

peptide synthesis using unprotected linear peptides as precursors.²² Mechanistically, this method first entails the installation of azide through Fmoc-SPPS at the N-terminus, and then installation of the phosphine thioester at the C-terminus by thioesterification using thiophosphine thiols. Subsequently, cyclization occurs between the azide and the phosphine thioester to generate cyclic iminophosphorane, followed by *S*-to-*N* acyl transfer, and hydrolytic elimination of iminophosphorane to form an amide bond (Scheme 1b). This reaction can be employed to obtain medium-sized cyclic peptides, which is compatible with any amino acid sequence compared to NCL, for example, chemically selective head-to-tail cyclization could be achieved under mild conditions. However, the preparation of peptide precursors by this method is relatively tedious, and the yield is rather low, which is subjected to further optimization.

2.1.3. α -Ketoacid-hydroxylamine ligation-mediated cyclization. In 2006, Bode and coworkers developed a new chemically selective α -ketoacid-hydroxylamine (KAHA) ligation method to link two unprotected peptide fragments *via* an amide bond, with water/alcohol and carbon dioxide as the by-products.²³ Regarding its mechanism, type-I KAHA ligation is initiated usually by a chemoselective ligation reaction between N-terminal hydroxylamine (HA) and C-terminal α -keto acid (KA) in aqueous solution under mild conditions, whereas an amide bond is formed at the ligation site (Scheme 2a). In 2012, Bode and coworkers demonstrated the good compatibility and practicality of using type-I KAHA ligation to prepare cyclic peptides with different ring sizes and sidechain functional groups.²⁴ However, the yield of the type-I KAHA ligation was generally

low, and unwanted epimerization occurred due to the easy oxidation of the N-terminal peptide hydroxylamine. Subsequently, the authors developed type-II KAHA ligation by introducing stable hydroxylamine derivatives, such as O-substituted hydroxylamine and 5-oxaproline, at the N-terminus of the linear peptide chain under standard Fmoc SPPS conditions.²⁵ In the modified version, the C-terminal keto acid could react with the N-terminal 5-oxaproline to produce a homoserine peptide residue and a lactam linkage (Scheme 2a). This mechanism is more suitable for peptide and protein synthesis. However, although the type II KAHA ligation effectively restrains the facile oxidation of free hydroxylamine in type I, more severe epimerization was observed in a few cases.

2.1.4. Serine/threonine ligation-mediated cyclization. Serine/threonine ligation (STL) was published by Li and coworkers in 2010.²⁶ They were the first to use a peptide fragment with an N-terminal serine or threonine to connect with another peptide with a C-terminal salicylaldehyde ester (formed from *N*-acyl benzimidazolone (NBzazolone) and salicylaldehyde dimethyl acetal on the resin, followed by phenolic hydrolysis) (Scheme 2b). Mechanistically, the ligation process involves the formation of oxazolidine by reversible imine trapping of the 1,2-hydroxylamine bifunctional group of the N-terminal serine or threonine residue with the C-terminal salicylaldehyde ester's aldehyde group. The subsequent O-to-*N* acyl transfer generates the *N*,*O*-benzyl acetaldehyde-linked stable cyclic peptide intermediate. After acid hydrolysis, the native cyclic peptide Xaa-Ser/Thr bond is yielded at the linking site. STL ligation had been successfully used in the cyclization of peptides with various sizes and side chains without protection and in the synthesis of



Scheme 2 Selected representative ligation-mediated peptide macrocyclization strategies. (a) α -Ketoacid and hydroxylamine (type-1) and 5-oxaproline (type-II) KAHA ligation; (b) serine and salicylaldehyde ester ligation (serine/threonine ligation, STL).



some natural cyclic peptides.^{27,28} It is worth noting that STL ligation can be applied to the synthesis of some small-size cyclic peptides, *e.g.*, cyclic tetrapeptide, to ensure good yield, while maintaining a high monomer ratio without epimerization.²⁹ In 2018, Li and coworkers developed an STL ligation method for aspartic acid. An N-terminal γ -amino alcohol was used instead of Ser/Thr for imine capture, loop tautomerization, and *O*-to-*N*-acyl transfer. This ligation was even extended to the use of any amino acid with an α , β -hydroxyl group at the N-terminus.³⁰

2.2. Thiol-based intramolecular cyclization

2.2.1. Disulfide bridges. Although the abundance of cysteine in nature is only about 1.9%, most cysteine sidechain thiols exist in the form of critical disulfide bonds in proteins and other secondary metabolites, which are usually used to stabilize their tertiary structure and conformation.³¹ The side-chain thiols of cysteine can be easily bridged in an oxidative environment,³² and they are also prone to thiol exchange. Hence, it is difficult to precisely control the site of disulfide bond formation on peptides or proteins when there are multiple cysteine residues. Thus, to overcome the problem of site selectivity, Wu and coworkers adopted the orthogonal cysteine pairing method³³ with the use of unnatural amino acid, penicillamine (Pen),³⁴ to reduce the generation of unfavored regional isomers because heterodisulfide Cys–Pen pairing was more favored than the formation of Cys–Cys/Pen–Pen homodisulfides. Although this approach was effective in minimizing the final number of isomers produced and realized rational folding of multicyclic peptides without protective groups and sequence manipulation, its wider applications is often hampered due to the need for penicillamine.

In 2020, Hayashi and coworkers developed a disulfide-driven cyclic peptide synthesis (DdCPS) strategy and successfully synthesized some cyclic peptide natural products.^{35,36} Firstly, on Npys-Cl resin, they prepared a disulfide crosslink between two peptides with two different sulfur-containing peptide fragments, and then cyclized the disulfide-bridged peptides using either thioester ligation or conventional amide coupling methods. Asymmetric disulfide peptides with high purity could be obtained, but this method required over ten steps of solid-phase reaction on the resin, leading to very low product yields. In fact, the disulfide bonds were not stable in most cases.³⁷ Regarding the production of synthetic cyclic peptides and proteins, it is usually preferred that disulfide bonds are reduced to the more stable thioacetal³⁸ or replaced with lactams, thioethers, *etc.*

2.2.2. Thioether bridges. The unique reactivities of cysteine sidechain thiols (*e.g.*, participating in thiol exchange, free radical, hydrogen transfer, electron transfer, hydroxid transfer, and metal binding reactions) makes cysteine particularly important.³⁹ Alkylation and arylation reactions of thiols have long been used for peptide macrocyclization. In 2005, Dawson and coworkers developed a method based on chemically selective nucleophilic substitution reactions between thiol and bromoacetyl groups (Scheme 3a). Sidechain-to-sidechain

cyclization was achieved in aqueous buffer with a pH of 8.4.⁴⁰ In 2022, Xiong and coworkers took advantage of a class of purine-based aryl sulfide reagents that they developed on the sidechains of amino acids (Lys, Asp, Tyr, *etc.*), and allowed them to selectively undergo on-resin one-pot nucleophilic aromatic substitution cyclization with deprotected cysteine to prepare a series of cyclic peptides containing aryl sulfide⁴¹ (Scheme 3b).


In 2010, an efficient, photo-initiated, free radical-mediated thiol–ene addition was used for cyclizing peptides. Anseth and coworkers, on Arg-Gly-Asp (RGD) model peptides, exploited cysteine as the thiol source to cyclize with allyloxy carbon (Alloc)-protected lysine containing different active olefin moieties. Thioether bridges were generated on-resin by ultraviolet light and free radical initiators.⁴² An intermolecular version was carried out by Li and coworkers using the amino acid Ac-Cys-OH.⁴³ Similarly, Li and coworkers further actualized a thiol–alkyne variant by clicking cysteine and alkyne-containing unnatural amino acids,⁴⁴ but it delivered a mixture of *E*-and *Z*-isomers (Scheme 3c).

Another strategy to employ thiols for solid-phase peptide macrocyclization involves the thia-Michael addition, which occurs between thiols and electron-deficient alkenes. Thioether bonds are formed in the presence of a base or a nucleophilic catalyst. In 2018, Kloxin and coworkers used the commercially available 2-chloroethanesulfonyl chloride to mount the vinyl sulfonamide group, a Michael acceptor, on primary or secondary amines to cyclize with thiol, a Michael donor, on resin; high conversion rates were obtained in a very short time.³⁷ In 2020, Brimble and coworkers successfully documented a solid-phase peptide macrocyclization strategy *via* the on-resin installation of allenamide on peptides for the chemoselective conjugate addition of the allene with thiols.⁴⁵ Mechanistically, tautomerization *via* base-catalyzed alkyne-to-allene isomerization occurs spontaneously and irreversibly at near neutral pH (Scheme 3d). The length of the bridging unit can be adjusted by using a lysine isobody, such as ornithine, or by adding an additional aminoalkyl chain, such as 6-aminocaproic acid.

2.3. Imine-based intramolecular cyclization

2.3.1. Aldimine condensation of the terminal amino group. Inspired by the enzymatic machinery of non-ribosomal peptide synthetases (NRPS) for cyclic peptide bioproduction, in 2017, Baran and coworkers developed a simple peptide macrocyclization method that directly and chemoselectively condensed the N-terminal amino group with the C-terminal aldehyde of unprotected linear peptides⁴⁶ (Scheme 4a). In aqueous solution, the amine and the aldehyde could spontaneously and reversibly create a macrocyclic imine, which could then be captured by different nucleophiles to form unnatural structures at the loop closure site for further derivatization. In the case of external nucleophiles, *e.g.*, potassium cyanide (KCN) and sodium cyanoborohydride (NaBH₃CN), α -aminonitrile or secondary amines at the ring-closure site could be generated, respectively, for internal nucleophiles, such as the indole,






Scheme 3 Selected representative strategies of thioether-based peptide macrocyclization with cysteine's thiols. (a) Nucleophilic substitution (S_N2); (b) nucleophilic aromatic substitution (S_NAr); (c) solid-phase photo-initiated thiol–ene click reaction; (d) on-resin installation of an allenamidyl group for thia-Michael-type click addition.

imidazole, thiol, and selenol adjacent to the N-terminal amino group, and various heterocycles could be fabricated. In 2019, Raj and coworkers reported a “CyClick” strategy to first form a cycloimine by the condensation between the N-terminus of the peptide and the C-terminal aldehyde, followed by the nucleophilic attack of the second amide nitrogen on the cycloimine to give a stable 4-imidazolidinyl group⁴⁷ (Scheme 4b). Given that the linear imine intermediate formed by the intermolecular reaction between two peptides could not activate the amide bond, this strategy could proceed even at high concentrations without dimer formation. In addition, the 4-imidazolidinone could be used as a turn-inducing element to bolster the intramolecular hydrogen bonding, conformational rigidity, and enzyme stability. Furthermore, this reaction endured with


high stereoselectivity, high substrate scope, and fast kinetic profile in dimethylformamide (DMF)/ H_2O .

2.3.2. Ketimine/aldimine condensation of lysine's amino group. In 2016, Gao and coworkers introduced a synthetic amino acid possessing 2-acetylphenylboronic acid, AB_3 , which could easily react with the amino group on the adjacent lysine sidechain to obtain monocyclic, and even bicyclic peptides through responsive intramolecular iminoboronate formation⁴⁸ (Scheme 5a). At neutral pH, the iminoboronate-cyclizing peptides exhibited surprisingly robust stability against interference from other biomolecules; however, these reversible iminoboronate linkages were found to be susceptible to acids, bio-oxidants, and exogenous small-molecule nucleophiles. Upon reduction with $NaBH_3CN$, the





Scheme 4 Selected representative strategies of imine-based peptide macrocyclization. (a) Aldehyde and terminal amino group condensation; (b) aldehyde and terminal amino group condensation, and then nucleophilic imine addition cascade.



Scheme 5 Selected representative strategies for imine-based peptide macrocyclization: (a) 2-acetylphenylboronic acid and lysine amino group condensation, then reduction; (b) oxoaldehyde and lysine amino group condensation, followed by imidazopyridinium grafting.

reduced aminoboronic-based cyclic peptides could be irreversibly trapped (in both diastereomers) and stabilized. This rapid and stimuli-responsive iminoboronic cyclization mechanism holds promise in a wide range of bioapplications with peptides and proteins. In 2024, Kodadek and coworkers presented an imidazopyridinium grafting strategy, during SPPS, by sequential trapping a reversible intramolecular imine linkage (formed between the lysine sidechain and terminal oxoaldehyde) with a 2-formyl/2-keto-pyridine. The resulting positively charged macrocyclic peptides demonstrated much better passive cell membrane permeability than expected for “beyond rule of 5” molecules⁴⁹ (Scheme 5b).

Most literature-reported imine-mediated intramolecular cyclization methods for peptides tolerate various amino acid sidechains and undergo few oligomerizations based on the

reversible imine formation mechanism. These linear peptide precursors containing C-terminal aldehydes can be readily prepared by Fmoc-SPPS, and the internal aldimines formed are capable of introducing a variety of modifications for conformational and structural regulation of the resulting cyclic peptides.

2.4. Multicomponent intermolecular stapling


Multicomponent intermolecular peptide stapling strategies furnish new modes and choices of reaction sites (e.g., in-between) for macrocyclization other than only at both termini in NCL; more importantly, the introduction of new linkages of rigidity and new functional handles creates new opportunities in this field.

2.4.1. Stapling between the natural amino acid residues. In a two-component peptide stapling process (*i.e.*, a type of sidechain-to-sidechain cyclization), when an external component reacts intermolecularly and builds a linker on one of the residues on a peptide, the subsequent second reaction becomes an intramolecular cyclization, which makes the stapling more favorable and avoids the tedious attachment of multiple unnatural linkers onto the peptide. The stapling strategy of exploiting and covalently linking the sidechain thiol of cysteine to different crosslinkers has been, particularly and considerably, developed in recent decades.^{50–52} Taking advantage of the binding propensity of the thiols in cysteine to palladium, in 2015, Pentelute, Buchwald and coworkers disclosed a selective arylation protocol for cysteine mediated by an organometallic palladium reagent (Scheme 6a). They chose various readily available aryl halides and trifluoromethanesulfonate (triflate) precursors to directly prepare the ambiently stable and long-storable solid palladium reagents for efficient and highly chemoselective cysteine aryl coupling. By using a reagent with two electrophilic aryl metal centers crosslinked by an acetophenone moiety, double cysteine arylation, and thus direct stapling was successfully achieved.⁵³ In 2018, the authors employed a biaryl phosphine-supported palladium reagent to selectively transfer an aryl group containing an O-phenyl carbamate substituent to a cysteine residue, which could be further selectively crosslinked with lysine in proximity *via* urea bond formation⁵⁴ (Scheme 6b). In 2024, Jbara and coworkers developed an orthogonal late-stage multiple palladium(II) (*i.e.*, Pd(II)OAc, Pd(II)Cl₂, and Pd(II) complex with bulky biaryl phosphine ligands)-mediated C–S bond cleavage (*i.e.*, chemoselective S-decaging from acetamidomethyl (AcM) protective group) and

C–S bond formation (site-selective *S*-arylation, and other S-modifications) strategy to efficiently and site-selectively stepwise manipulate multiple cysteine sites on demand under different aqueous conditions without interfering with the protected ones.⁵⁵ Based on this method, precision peptide and protein stapling by double *S*-arylation of cysteines within 3–6 residues were reported (Scheme 6c).

In 2019, Li and coworkers⁵⁶ and Perrin and coworkers⁵⁷ independently reported the peptide macrocyclization strategy based on isopeptide bond and isoindole formation. Both strategies used phthalaldehyde (OPA) to react with a lysine and cysteine within an unprotected peptide sequence, which could be saliently adoptable for bicyclic peptide synthesis under mild and metal-free conditions (Scheme 7a). Li and coworkers investigated the further modification of the cyclic peptide products by using dimethylacetamide (DMAC) or *N*-maleimide derivatives to construct new structures and attach new functional groups. Alternatively, in the study by Perrin and coworkers, different OPA analogues were evaluated and utilized to produce a few bicyclic peptides with different fluorescence properties.


With the help of the anchoring effect of aldehyde-based “glue” molecules on the ϵ -amino group of lysine, in 2021, Chen and coworkers devised a chemoselective cooperative stapling strategy for the natural peptides lysine and tyrosine/arginine using formaldehyde as the linchpin under mild conditions⁵⁸ (Scheme 7b). In this reaction, after the reversible condensation of the ϵ -amino group of lysine with formaldehyde to form imine, it could be crosslinked to the adjacent tyrosine or arginine residues. In the case of tyrosine, the nucleophilic *ortho*-carbon of the sidechain phenol triggers a Mannich-type




Scheme 6 Selected representative strategies of multicomponent peptide stapling between natural amino acid residues with divalent organometallic reagents. (a) Between two cysteines; (b) between a lysine and a cysteine; (c) among multiple cysteines in a stepwise, site-selective manner.




(a)




(b)



(c)



(d)



Scheme 7 Selected representative strategies of multicomponent peptide stapling between natural amino acid residues with divalent aldehyde-based linkers. (a) Phthalaldehyde between a cysteine and a lysine; (b) formaldehyde between a lysine and a tyrosine/arginine; (c) phthalaldehyde and (d) α -ketoaldehyde between two primary amines (lysines or lysine with the N-terminus).

cyclization, followed by rearomatization to form a stable benzylamine crosslinked product. Regarding arginine, after nucleophilic attack of the sidechain guanidine group on the imine, the

secondary amine of the intermediate forms the imine with formaldehyde, resulting in after another nucleophilic attack, a stable tetrahydropyrazine-stapled product, as well as its exo-isomer.

In 2022, Chen and coworkers reported that OPA could be easily condensed with two primary amines of peptides under mild water conditions in the absence of thiols. They devised different tail-to-side and side-to-side OPA-based macrocyclization of unprotected peptides by suturing two amino groups⁵⁹ (Scheme 7c). This method was ultrafast and highly compatible with a wide range of peptide substrates, where the isoindolinimine linchpin could be further functionalized with various electron-deficient electrophiles. In 2024, the authors further used different α -ketoaldehyde reagents to crosslink two amino groups, grafting a unique imidazolium moiety into the macrocyclic peptide products. Here, the use of hexafluoroisopropanol (HFIP) solvent was the key to achieving high reactivity, distinctive chemoselectivity for lysine over arginine, and reaction cleanliness⁶⁰ (Scheme 7d).

Besides the well-explored cysteine and lysine residues, in 2023, Sun and coworkers described a chemically selective cross-linking method for tryptophan residues, which was achieved by using dimethyl sulfoxide and visible light.⁶¹ The C–S structure was formed by irradiating a blue light emitting diode with thiophenol at room temperature, cyclizing unprotected peptides with high compatibility with most amino acid sidechains. Although the reaction suffered from low product yields, it provided a new perspective. In 2023, Yu, Li, Jiang and coworkers utilized bifunctional triazine moieties to react and staple the phenolic hydroxyl group of two tyrosines of the unprotected peptide⁶² (Scheme 8).

2.4.2. Stapling with modified or unnatural amino acids. As a commonplace reaction in nature to build carbon–carbon bonds and six-membered ring systems, Diels–Alder [4+2] cycloaddition has long attracted significant attention from chemists since its inception for synthesis of complex molecules. In 2019, Moellering and coworkers demonstrated the feasibility of Diels–Alder [4+2] cycloaddition for peptide macrocyclization using moderately activated 2,4-hexadiene and well-characterized maleimide dienophiles⁶³ (Scheme 9a). They synthesized the corresponding diene-containing amino acid Fmoc-Cys(2,4-hexadiene)-OH, (or else furan-containing Fmoc-(2-furanyl)alanine), through SPPS involving orthonormal-protected cysteine (*t*BuS-), orthonormal-protected lysine (Mmt-) deprotection and *N*-maleimide-glycine acylation. A rapid spontaneous reaction was followed by almost quantitative formation of cyclic peptide products. The authors discovered that the Diels–Alder cycloadduct linkage was preferentially produced with embedded stereochemistry and stabilized peptide conformation (α -helix) in aqueous medium. It could also

be combined with other reactions, such as olefin metathesis, to achieve multiple stapled peptides under rational design and stepwise strategic manipulation, and attached with other functionalities to influence, to a large extent, the helicity and bioactivities of the cyclic peptide sequences.


In 2019, Wang and coworkers innovatively employed 1,4-dinitroimidazole, a bifunctional biological coupling reagent, for protein functionalization and peptide macrocyclization.⁶⁴ In neutral aqueous solutions, 1,4-dinitroimidazole (1,4DNIm) rapidly underwent a substitution reaction with cysteine thiol; in contrast, in the absence of cysteine, 1,4DNIm could react with, under base catalysis, the amino group of lysine with high selectivity through ring-opening and ring-closing mechanisms to form stable peptide conjugates. Cyclization and double cyclization with unprotected peptides were accomplished by using double 1,4DNIm crosslinkers (Scheme 9b). In 2021, Chan, Long, Wong and coworkers disclosed a solid-phase peptide macrocyclization strategy *via* *in situ* dipyrin construction, where dipyrin was utilized as a multifunctional staple linker.⁶⁵ The authors first attached commercially available pyrrole moieties onto both N-terminal and amino groups of lysine of resin-bound peptides, and then coupled the two pyrrole moieties with various aldehydes (Scheme 9c). Various alkyl and aromatic groups, as well as different functionalities, could be installed onto the *meso*-position of dipyrin (*e.g.*, for fluorescence imaging and sensing), which could also be used as a further reaction site to culminate in highly challenging but sought-after bicyclization.

In recent years, many novel structural and functional staple crosslinkers have been developed for the more precise and efficient construction of complex polycyclic peptide structures, which will be described in the Section 5 of peptide polycyclization.

2.5. Multicomponent reaction-mediated cyclization

Different from NCL, the application of multicomponent reactions (MCRs) in peptide macrocyclization (similar to the previous session) allows not only modification of cyclic peptide backbones, but also the introduction of new linkages and functionalities.


2.5.1. Ugi reactions. In 2010, Yudin and coworkers pioneered the use of the Ugi-typed four-component reaction for peptide macrocyclization with the aziridine aldehyde dimer, where high yields of challenging medium-sized rings could be obtained in a relatively very short time (<10 h) with high diastereoselectivities⁶⁶ (Scheme 10). Regarding the concerted



Scheme 8 Multicomponent peptide stapling between natural amino acid residues with divalent triazine linkers.




(a)




spontaneous
on-resin, DMSO,
45 °C, 4 h

(b)



(c)




Scheme 9 Selected representative strategies of multicomponent peptide stapling between modified amino acid residues. (a) Diels–Alder [4+2] cycloaddition; (b) 1,4-dinitroimidazole-based skeletal recasting; (c) on-resin dipyrin construction.

addition mechanism, this protocol first proceeds *via* a zwitterionic iminium ion intermediate (*via* the condensation of the aldehyde with the N-terminal amino group), which then upon an attack by the isocyanide (alkyl or aryl), generates an imidoanhydride intermediate (this synergistic addition mechanism dictates and explains the unusual stereoselectivity of this protocol) subjected to subsequent attack by the C-terminal carboxylate to cyclize with the embedded acyl aziridine ring in the backbone. After *O*-to-*N* acyl transfer and ring-opening of the aziridine ring by nucleophiles, the final cyclic peptide can be obtained. With the trifluoroethanol (TFE) solvent being strategically chosen for stabilization of the peptide secondary structure and promotion of polar interactions for the precyclization of the zwitterionic species, this modified Ugi-protocol overcomes the traditional low-yield preparation with mono-functional aldehydes and inferior diastereoselectivity; in particular, the workup procedure only involved simple precipitation. Ugi reactions were also applicable to sidechain-to-sidechain and sidechain-to-termini peptide macrocyclization,⁶⁷ which

were faster and far more efficient than the head-to-tail version. In addition, the sidechain involved in these multicomponent reactions can provide higher structural diversity and flexibility, as exemplified by, in 2020, Rivera, Domling and coworkers, who employed two carboxylate sidechains or unnatural amino acids to be coupled with different bifunctional staples, thereby enabling the conjugation of various moieties on the cyclic peptides and fine-tuning the conformation and bioactivities⁶⁸ (Scheme 10).

2.5.2. Petasis reactions. The Petasis reaction, also known as the boron–Mannich reaction, is a three-component condensation reaction consisting of an aldehyde/ketone, an amine, and a boronic acid. From the perspective of late-stage peptide modification, the Petasis reaction is relatively easier to control than the four-component Ugi reaction (exhibiting promiscuous reaction mechanistic pathways). In 2019, Yudin and coworkers disclosed a Petasis assembling approach to yield a diverse range of conformationally stable macrocyclic peptides with endocyclic amines (due to the intramolecular hydrogen




Scheme 10 Selected representative Ugi reaction-based peptide macrocyclization strategies.

bonding network with adjacent amide groups), which can act as new synthetic handles for post-cyclization modifications.⁶⁹ In 2023, Spring and coworkers reported a peptide stapling and labeling approach through tryptophan-mediated Petasis reaction with on-resin-modified lysine⁷⁰ (Scheme 11). In this work, after the lysine (Alloc) was deprotected on the resin, the required boronic acid was introduced through a simple amide coupling reaction, which then reacted with the α -hydroxy acetic acid (formed by the bare indole in tryptophan and glyoxylic acid) chemoselectively to complete the cyclization. This novel

approach was simple to perform and easy to incorporate biologically relevant and functional tags (e.g., cell-penetrating motifs and fluorescent dyes), while also exhibiting a broad substrate scope and strong functional group tolerance (*i.e.*, suitable for peptides bearing a C-terminal acid/amide).

2.5.3. Other multicomponent reactions. In 2016, Yudin and coworkers adopted their zwitterionic control strategy and disclosed an MCR involving an aldehyde, unprotected linear peptide, and (*N*-isocyanimino)triphenylphosphorane for preparing, in one-step, head-to-tail cyclic peptidomimetics with a



Scheme 11 Selected representative Petasis reaction-based peptide macrocyclization strategies.



1,3,4-oxadiazole (a proteolytically stable isostere of amide linkage) backbone moiety⁷¹ (Scheme 12). Mechanistically, upon the formation of an electrophilic imine between the N-terminal amine and the aldehyde, nucleophilic attack by (*N*-isocyanimino)triphenylphosphorane occurred, generating a modified peptide chain with negatively C-terminal carboxylate. In contrast, under electrostatic attractions, the positively charged N-terminal phosphorane drove the cyclization to furnish a mixed anhydride intermediate. Subsequently, the pendant exocyclic amine (from the *N*-isocyanimino) intercepted the mixed anhydride and underwent an aza-Wittig-type reaction to finally furnish the 1,3,4-oxadiazole-grafted peptidic macrocycle. A wide range of ring sizes, *e.g.* 15–24 membered, could be obtained by varying the length and composition of the linear peptides, while new alternative functional moieties could be easily introduced. Side oligomerization could be suppressed even with more restricted 4-mer peptide sequences and at high concentrations of 5–100 mM peptide. In particular, the non-canonical oxadiazole motif served as an endocyclic control element that promotes and stabilizes a unique intramolecular hydrogen-bond network, leading to macrocycles with conformationally rigid turn structures. However, two diastereomers were yielded.


2.6. Other miscellaneous non-catalytic cyclization strategies

Condensation agents are a class of peptide coupling reagents that are used to promote the direct condensation of carboxylic acids with amines or alcohols to form amide or ester bonds, which play a pivotal role in the synthesis of peptides. In recent years, Zhao and coworkers developed a new type of ynamide coupling reagent, which can be widely used in the synthesis of amides, esters, macrolides, peptides and thiopeptides.⁷² In 2018, the authors utilized the ynamide, *N*-methylbenzenesulfonamide (MYTsA), and monothiocarboxylic acids as thioacyl donors to efficiently synthesize linear thiopeptides without racemization. During this process, amino acid functional groups such as OH, CONH₂, and the NH groups


of indoles could be protection free, but a long aminolysis reaction time was required, which limits its practical application potential.⁷³ Based on the previous work, in 2022, the authors successfully extended the applicability of ynamide-mediated peptide bond formation to various peptide fragment ligation, head-to-tail cyclization, and even SPPS conditions.⁷⁴ This strategy employed *N*-methylbenzenesulfonamide (MYMsA) to robustly form a stabilized intermediate to promote peptide bond formation in a one-pot, two-step manner. High yields of the cyclic products were obtained with excellent chemoselectivity and no detectable epimerization issues compared with other common peptide coupling reagents (Scheme 13a).

The 1,2-aminothiol of the N-terminal cysteine could easily condense with aldehydes to form thiazolidines, in the protocol first reported by Tam and coworkers to prepare cyclic peptides in 1996.⁷⁵ In their method, the starting C-terminal ethanol-aldehyde ester could first be obtained by the oxidation of glycerol ester under solid-phase peptide synthesis (SPPS). By adjusting the pH value to 5.5 in aqueous solution, an intramolecular condensation between the N-terminal cysteine and C-terminal ethanolaldehyde ester could be triggered to form a thiazolidine intermediate. Subsequently, raising the pH value to 5.9 could enable another intramolecular rearrangement to achieve *O*-to-*N* acyl transfer, thus completing the cyclization (Scheme 13b). Only through tuning the pH environment, this reaction could be very simply, conveniently and widely applicable to unprotected peptide main chains without special sequence requirement, except for the two terminal groups. However, the reaction rate of this method is too slow and the inevitable introduction of a new stereocenter on the C-5 carbon of the thiazolidine ring leads to a pair of undesired diastereomers.


In 2023, Zhang and coworkers reported a chemoselective natural peptide cyclization (NPC) strategy⁷⁶ (Scheme 14a). In this strategy, the pH of the aqueous solution is adjusted to make the C-terminal carboxylate the major nucleophilic residue to preferentially combine with the isonitrile, thereby



Scheme 12 Selected representative other multicomponent reaction-based peptide macrocyclization strategies.



Scheme 13 Selected miscellaneous non-catalytic peptide macrocyclization strategies: (a) with ynamide; (b) via thiazolidine grafting.

Scheme 14 Selected other miscellaneous non-catalytic peptide macrocyclization strategies: (a) with isonitrile; (b) via hydroxamic acid–haloacetamide ring closure; (c) with NaNO₂.

forming a mixed-anhydride adduct. Subsequently, the activated C-terminus is captured by the N-terminal cysteine thiol group (SH) *via* intramolecular thiolytic, leading to the chemically selective formation of thiolactam. Similar to the NCL reactions, the NPC reaction ends by N-to-S acyl transfer. These NPC strategies enabled the intramolecular cyclization of unmodified and protected peptides without the excessive use of additives, organic reagents and solvents. The authors synthesized more

than 60, 5- to 20-membered cyclic peptides with simple operation in high efficiency.

In 2024, Kim and coworkers introduced a reversible cyclization methodology for unprotected peptides containing a C-terminal hydroxamic acid and N-terminal electrophile⁷⁷ (Scheme 14b). In this method, the C-terminal hydroxamic acid and N-terminal haloacetamide were attached *via* SPPS, followed by the efficient cyclization of unprotected, thiol-free amino acid



residue precursor peptides of various lengths and compositions in water under mild conditions. Noticeably, the cyclized peptide could be re-opened by adding excess samarium iodide to reduce the formed hydroxamic linkage in the presence of typical amino acid residues. This hydroxamic acid-driven cyclization strategy embraces certain characteristics, as follows: (i) high compatibility for unprotected peptides, (ii) high stability for the cyclic products, and (iii) high cyclization propensity for low molecular-weight short peptides, rather than undesired oligomerization.

In 2022, Raj and coworkers developed a novel and expeditious arene triazene strategy, which was chemoselective for secondary amines and *p*-amino phenylalanine on unprotected peptides, with the use of NaNO_2 , for macrocyclizing peptides, while generating inbuilt triazene chromophores of distinct UV absorbance at the site of cyclization. Saliently, the resulting triazene cyclic peptide products were formed within a minute and found to be highly stable at neutral pH and under harsh conditions. Furthermore, they could quickly respond to various external stimuli, *e.g.*, UV radiation and acidic conditions, leading to reversible ring-opening. In particular, a very broad substrate scope was reported, including different amino acid compositions with all *L*-amino acids without any turn inducers, various secondary amines and sequences with multiple arginine residues; and different chain lengths (4–20 amino acids)⁷⁸ (Scheme 14c).

3. Catalytic chemical macrocyclization strategies

Transition metal catalysis have significantly advanced and revolutionized modern synthetic organic chemistry in recent decades. From copper-catalyzed alkyne–azide click cycloaddition to ruthenium-catalyzed ring-closing olefin metathesis, transition metal-based catalytic strategies for peptide macrocyclization have been proven to be highly feasible, efficient, and attractive. As a few examples, photoredox catalytic reactions, cross-coupling reactions, C–H activation, aryl/alkylation of heteroatoms, and many others have been strategically developed. In general, there are two types of mechanistic pathways, where in the first, the metal catalyst activates one of the peptide functional groups for further reacting with another functionalized sidechain or backbone. In the second, the metal catalyst binds two reactive functional groups, and thus the C–C or C–heteroatom bonds can be eventually formed for ring closure. Both pathways depend on the final reductive elimination step in the catalytic cycle. All these strategies provide a completely new and significant synthetic paradigm and platform to access macrocyclic peptides beyond the well-known lactamization and NCL.

3.1. Azide–alkyne click cycloaddition-mediated cyclization

In 2001, Kolb, Finn and Sharpless established the featured “click chemistry”.⁷⁹ In 2002, Meldal and coworkers applied the copper(i)-catalyzed azide–alkyne cycloaddition click reaction


(CuAAC) for the ligation of peptides.⁸⁰ In the presence of unprotected sidechains, this reaction could effectively connect two peptide fragments with a triazole. In 2005, Burgess and coworkers documented the first synthesis of a head-to-tail cyclic peptide by CuAAC, in either organic solvents or water under mild conditions, forming 1,4-disubstituted 1,2,3-triazole-embedded cyclopeptides⁸¹ (Scheme 15a). These seminal works laid the theoretical foundation for the applications of CuAAC in peptide chemistry, given its simple operation, high chemoselectivity, and feasibility in the peptide synthesis (the reaction conditions are fully compatible with unprotected sidechains). In particular, it was found that both the synthetic 1,4-disubstituted 1,2,3-triazole and the natural *trans*-amide bond would have similar spatial structures, which could be used as a β -turn component.^{80,81} All these advantages are important factors for the wide applications of CuAAC in bioconjugation and biomaterials science.

The synthesis of cyclic peptide precursors by CuAAC entails the pre-installation of both azide and alkyne moieties on peptides. The azide group can be transferred to the terminal or primary amine in the lysine sidechain by diazo transfer, while the alkyne group can be introduced with unnatural amino acids or chemical modifications of natural amino acid sidechains. The introduction of C-terminal alkynes can be achieved by the Fmoc-SPPS silyl-based alkyne modifying (SAM) linker method.⁸² CuAAC-based peptide macrocyclizations have been implemented in the form of head-to-tail, sidechain-to-sidechain and sidechain-to-head/tail fashions, which can be carried out in both solid/liquid phases. The double CuAAC-based macrocyclization method was reported by Meldal and coworkers in 2011,⁸³ which played an important role in stabilizing the secondary peptide structure by the rigid triazole moieties instead of flexible disulfide bridges. A second approach, which involves the stapling of two unnatural/modified azide sidechains with a dialkynyl external component, was developed by Spring and coworkers in 2014⁸⁴ (Scheme 15b). This bioorthogonal two-component stapling method can also be utilized to conjugate other peptides, fluorophores, and functional handles to diversify the functions of the stapled peptides. In 2017, Pedersen and coworkers developed the third generation of the CuAAC strategy. Two amino acid residues bearing azides were combined with 1,3,5-triethynylbenzene to form a staple, with the third free alkyne group being further facilely functionalized or dimerized to obtain more complex and diversified cyclic peptides⁸⁵ (Scheme 15c).


Although click chemistry is a powerful tool for bioconjugation, especially for proteins and peptides, and even macrocyclization for peptides with rigid nitrogen-based heterocyclic linkages, the CuAAC reaction has certain limitations. Firstly, monitoring the intramolecular CuAAC reaction can be a great challenge because the starting material and the product have the same molecular weight. In addition, a major disadvantage of using the CuAAC reaction in biological systems is that copper species are prone to induce the formation of reactive oxygen species (ROS);⁸⁶ copper(i) is not stable enough in the physiological environment, which can be oxidized or chelated with




(a)



(b)



(c)



Scheme 15 Azide–alkyne click cycloaddition-based peptide macrocyclization strategies. (a) CuAAC and RuAAC; (b) and (c) click-stapling.


other biomolecules. In the worst-case scenario, it may lead to the oxidative degradation of proteins and peptides. Thus, to reduce the biotoxicity of copper ions, the use of tris(triazolylmethyl)amine-based ligands, such as tris(3-hydroxypropyl methyl)amine (THTPA) or tris(1-benzyl-1H-1,2,3-triazolyl-4-yl)methylamine (TBTA), can significantly reduce this oxidative damage. To avoid oxidation completely, the reaction should be carried out under anaerobic conditions. To this end, strain-promoted alkyne–azide cycloaddition (SPAAC), a copper-free click reaction, can serve as a complementary reaction and resolution. A variety of cyclooctyne reagents has been developed for this purpose, and SPAAC has been widely used in biomedicine.^{87,88}

3.2. Ring-closing olefin and alkyne metathesis-mediated cyclization

Compared with the establishment of click reaction, the development of alkene metathesis reaction underwent a much longer process. It took 30–40 years from the discovery of the

olefin metathesis reaction in the 1960s to its contemporary wide applications. With the development of the first and second ruthenium-based Grubbs catalysts for olefin metathesis in the 1990s,⁸⁹ the olefin metathesis reaction gradually became popular. In 2000, Verdine and coworkers synthesized full hydrocarbon bridging *α*-helical peptides using ring-closing metathesis (RCM)⁹⁰ (Scheme 16a). In this study, the concept of peptide stapling was proposed for the first time. It demonstrated the ability of RCM reaction to control the helical structure of protein by stapling. The RCM reaction is most commonly used in intramolecular reactions to generate cyclic systems, with its high tolerance to most functional groups, and its usually high product yield makes it highly suitable for modifying relatively large and functionally diverse molecules, *e.g.*, peptides and proteins. RCM-based peptide macrocyclization can be carried out in either the solid or liquid phase, and the hydrocarbon linkage has the advantage of mimicking the disulfide bond to manipulate the configurations of the resulting peptides and proteins. Various creative strategies have been





Scheme 16 Ring-closing metathesis-based peptide macrocyclization strategies. (a) RCM; (b) RCAM.

developed for peptide macrocyclization using RCM reactions with relatively more flexible alkene linkages.⁹¹

Given that each step in the RCM reaction mechanism is a reversible process, and two alkenes are to be released, the overall dynamic equilibrium of the reaction usually shifts to the product side. In the case of complex biomolecular structures such as peptides, the RCM process usually produces a mixture of *Z/E*-configuration alkenes. However, control of the olefin configuration for peptide synthesis remains challenging. In addition, the most common catalyst for the RCM reaction is the ruthenium-based Grubbs catalyst. However, this class of ruthenium reagents usually induces the decomposition of DNA, proteins, and other substances. To prevent the destruction of peptides by ruthenium, a large amount of Mg^{2+} ions^{92,93} is usually added for substrate protection. Yoshiya and coworkers actualized the ring-closing olefin metathesis of unprotected peptides in water by employing a water-soluble ruthenium catalyst, a large excess of $MgCl_2$, and/or acidic conditions, thereby generating three octreotide analogues.⁹³ However, another type of common RCM molybdenum-based catalyst was rarely used due to its lower activity.⁹⁴

Similarly, alkynes can also undergo metathesis reactions with other alkynes. The ring-closing alkyne metathesis (RCAM) necessitates catalytic high-valence tungsten and molybdenum-based complexes (Scheme 16b). In 2005, Liskamp and coworkers documented the first ring-closing alkyne metathesis for the synthesis of the alkyne mimics of thioether A, B, C, and (D)E ring systems of the lantibiotic nisin Z (with rigid rod-like alkyne linkages).⁹⁵ The authors used tungsten (W) complex-catalyzed RCAM to synthesize alkyne-bridged cyclic peptides containing 4–7 amino acid residues. Notably, the (D)E ring system of the nisin Z antibiotic was constructed by a combination of RCM and RCAM. The combined use of RCM and RCAM in bicyclic peptide synthesis could solve the selectivity problem of using only a single approach. In 2016, Furstner and coworkers developed an orthogonal RCM–RCAM method to achieve double peptide stapling.⁹⁶ In this method, the chosen Mo complex-catalyzed RCAM was chemically orthogonal to the Ru-catalyzed RCM, and thus peptides containing two alkyne and two alkene

functionalities could be cycled sequentially respectively, in high precision.

RCM and RCAM are very important in the synthesis of all-hydrocarbon stapled peptides. In 2023, Hu and coworkers introduced restrictive anchoring residues containing cyclobutene and synthesized a series of all-hydrocarbon stapled peptides containing different combinations of cyclobutanes using the RCM-based SPPS. Among them, the E7–E7 geometry-specific stapled peptide exhibited higher α -helicity and was found to be more biologically active than its typical hydrocarbon counterparts.⁹⁷ Because of the linear configuration of the alkyne groups, it is often necessary to have suitable preorganization for the cyclization of shorter peptide chains, where terminal alkynes with longer alkyl chain linkages can promote the reactions. In general, RCAM is less widely used in peptides than RCM.⁹⁶ However, control of the *Z/E* configuration of the double bonds can be achieved by the addition reaction of alkynes.

3.3. Photochemical reaction-mediated cyclization


Photochemical reactions have engendered many new and powerful chemical transformations over the past two decades. With the advances in the field of photochemistry and free radical chemistry, photocatalytic reactions have been extended for the macrocyclization of peptides. In addition to nonmetal catalyzed thiol–ene radical-type photochemical reactions, light-mediated peptide macrocyclization can also be performed using photoredox reactions catalyzed by photoactive transition metals, *e.g.*, iridium and nickel. Relatively flexible hydrocarbon, phenyl ether and thioether/thioamide linkages can be created in the macrocyclic peptide products.

In 2014, MacMillan and coworkers developed the Giese reaction for peptide ring formation.⁹⁸ In this reaction, iridium(III) catalyzed the oxidative decarboxylation of carboxylic acid to form free radicals under excitation by light, which then underwent 1,4-conjugate addition to the Michael receptor. The authors found that this oxidative decarboxylative process also applied to a variety of α -amino acids. In 2017, the authors proposed a decarboxylative macrocyclization method for peptides containing N-terminal Michael receptors⁹⁹ (Scheme 17a). In this method, upon light irradiation, the Ir(III) catalyst promoted C-terminal decarboxylation to form α -amino radicals. Subsequently, these radicals attacked the N-terminal Michael receptor for 1,4-addition, followed by the critical C–C bond formation to obtain the desired macrocycle, while providing electrophilic α -acyl radicals. The final association with electron-deficient radicals ended the photoredox catalytic cycle. This synthetic method tolerated most natural and non-proteinogenic amino acid sidechains (under protection, except cysteine). It was successfully applied to efficiently cyclize linear precursor peptides comprised of 3 to 15 amino acids.


Similarly, in 2016, Baran and coworkers disclosed a method for the macrocyclization of peptides based on the nickel-catalyzed Barton decarboxylation/Giese reaction with *N*-hydroxypythalimide (NHPI) redox-active esters.¹⁰⁰ It should be noted that this method did not rely on the photochemical




(a)




(b)



(c)



(d)



Scheme 17 Selected examples of photochemical peptide macrocyclization strategies. (a) Photoredox-mediated decarboxylative radical conjugate addition; (b) Ni/photoredox-promoted C(sp₂)-O cross-coupling; (c) photoredox-triggered Minisci reaction; (d) photochemical thio-ene reaction.

reactivity of the active ester. In 2019, Sciammetta and coworkers developed a photoredox Ni-catalyzed peptide C(sp₂)-O cross-coupling approach¹⁰¹ (Scheme 17b). This work was inspired by the pioneering work of MacMillan and coworker, who realized C(sp₂)-O coupling by photoredox nickel catalysis.¹⁰² They mounted a bromobenzoyl group at the N-terminus to perform Ni/photoredox catalytic reactions with the hydroxyl of serine and phenol sidechains of tyrosine. The successful formation of ether bonds between the two residues enabled the peptide to achieve sidechain-to-tail macrocyclization with high chemical selectivity in good yield.

In 2021, Chen and coworkers reported two methods for effectively constructing peptide macrocycles through a free radical-mediated intramolecular (Minisci) C-H alkylation reactions of glycines and N-heteroarenes, respectively, under

iridium/copper-based photoredox catalysis¹⁰³ (Scheme 17c). In this work, linear peptide precursors were first equipped with a C-terminal N-(acyloxy)phthalimide ester, which then cyclized with the α C-H bond of the N-terminal glycine or aryl C-H bond of N-heteroarene capping units under mild conditions, enabling the incorporation of lysine, homolysine, and various heteroarene-derived amino acid linchpins into peptide macrocycles. In 2024, Scanlan and coworkers achieved a rapid metal-free photochemical acyl thiol-ene cyclisation strategy in SPBS for fully unprotected peptides bearing a thioacid and alkene to deliver macrocyclic thiolactone peptides¹⁰⁴ (Scheme 17d). Concerning the underlying chemistry, γ -thioaspartic acid bearing the required thioacid on the side chain of aspartic acid (Asp) and allylglycine residues were tactically employed to avoid the unfavoured dethiocarboxylation side-reaction under the radical environment.



3.4. Cross-coupling reaction-mediated cyclization

$C(sp^2)-C(sp^2)$ bonds can be formed very efficiently and reliably *via* traditional transition metal-catalyzed cross-coupling reactions. Among them, Pd-catalyzed coupling reactions are the most typical and classical examples. Mechanistically, the transition metal is first inserted into the carbon-(pseudo)-halide bond by oxidative addition, then the two organic fragments are bound and joined by an organometallic intermediate (*via* migratory insertion, β -elimination, isomerization or trans-metallation, *etc.*), and finally the metal catalyst is regenerated by reductive elimination with the formation of a new carbon–carbon bond. Theoretically and ideally, most of the coupling reactions can be applied to the macrocyclization of peptides, provided that two suitable reactive groups are introduced in the peptides. For example, reactions such as Suzuki–Miyaura, Tsuji–Trost, Sonogashira–Hagihara, and Mizoroki–Heck can be in principle applied. Some examples show that the conditions of palladium-catalyzed cross-coupling reactions have a minimal effect on the enantiomeric purity of the resulting products; among which, Suzuki coupling, as a powerful palladium-catalyzed technique for modifying different carbon-(pseudo) halide bonds, has been shown to have good biocompatibility and bioorthogonality.¹⁰⁵ In fact, in reality, the application of traditional transition metal-catalyzed cross-coupling reactions in biomolecules is limited. Most of these reactions can only couple aryl groups or aryl groups with (sp^2) alkyl groups. In addition, the need for accurate pre-functionalization of peptides also imposes significant synthetic challenges.

In contrast to conventional cross-coupling reactions, C–H activation strategies enable the direct alkylation/arylation of natural amino acid side chains, promisingly avoiding the aforementioned issues. In recent years, there have been increasing examples of peptide modification and cyclization through C–H activation. The metals that can be used for C–H activation include palladium, manganese, and rhodium. The conjugated C–H can be derived from the C atoms of sp -, sp^2 -, or sp^3 - hybridization. Among the transition metal-catalyzed peptide macrocyclization strategies, C–H activation has become one of the best methodologies (possibly without pre-functionalization and workable on amino acid residues other than cysteine), in line with NCL, which has been considered an important tool for the late-stage functionalization of biomolecules.¹⁰⁶


Pd-catalyzed $C(sp^2)-H$ activation was first applied to the macrocyclization of peptides. In 2015, based on the previous first-time direct arylation¹⁰⁷ and macrocyclization¹⁰⁸ of indole, Albericio, Lavilla, and coworkers reported, for the first time, $Pd(OAc)_2$ -catalyzed $C(sp^2)-H$ activation for C–C bond formation and peptide stapling between the C2 site of tryptophan and iodinated phenylalanine or tyrosine residues¹⁰⁹ (Scheme 18a). They investigated the effect of the distance between the two reaction moieties on the conversion efficiency and showed that both the ring size and the conformation of the peptide were critical for the success of macrocyclization. Based on $C(sp^2)-H$ activation and olefination catalyzed by $Pd(OAc)_2$, Wang and

coworker developed a series of macrocyclization methods targeting the C-2 position of phenylalanine in the sidechain,¹¹⁰ *ortho*-phenyl position of the terminal methylbenzylacetamide,¹¹¹ *ortho*-phenyl position of N-terminal sulfonamide,¹¹² indolyl C2/C4 position of tryptophan,¹¹³ and N-terminal oxazole motif.¹¹⁴ In their works, the $AgOAc$ incorporated therein acted as an external oxidant to regenerate $Pd^{(II)}$ and restarted the catalytic cycle. These oxidative cross-coupling examples, which included a C–H activation step, avoided the need of pre-functionalization of amino acids. In 2020, Chen and coworkers published a versatile method of Pd-catalyzed picolinamide-directed intramolecular arylation of aryl and alkenyl C–H bonds of amino acid iodinated sidechains for the construction of $C(sp^2)$ -linked cyclophane (*i.e.*, biaryl-bridged and aryl-alkene-braced) peptide macrocycles.¹¹⁵ The N-terminal $C(sp^2)$ could be derived from either terminal alkenes or aromatic rings.

In effect, palladium-catalyzed $C(sp^3)-H$ activation in peptide chemistry is of utmost importance, given that it creates the possibility to exploit the peptide conformational constraints of the sidechains of native aliphatic amino acids. Inspired by the intermolecular arylation of $C(sp^3)-H$ bond of N-terminal amino acid catalyzed by Pd by Yu and coworkers,¹¹⁶ in 2016, Noisier, Albericio and coworkers reported the Pd-catalyzed late-stage $C(sp^3)-H$ activation for peptide stapling¹¹⁷ (Scheme 18b). Coincidentally, Wang and coworkers used almost the same conditions to link a peptide chain with an *N*-Phth-Ala sequence and an iodine-phenylalanine (Phe) in the form of a $C(sp^3)-C(sp^2)$ bond.¹¹⁸ This method could be performed in the solution or solid phase, without the need for external directing groups, demonstrating good compatibility with the sidechains of most amino acids. Given the rigidity of the aryl group at the junction, this method was found to be suitable for the cyclization of long-chain peptides. In 2018, Chen and coworkers used the iodobenzene or *p*-iodo-phenylalanine aryl sidechains of unnatural amino acids and removable the 8-aminoquinoline (AQ) auxiliary groups on the alkyl tail on either C/N-terminus to selectively cyclize linear peptide precursors of different designs to form a variety of cyclic peptides of medium and higher sizes.¹¹⁹ It is worth noting that this method could obtain a 37-membered macrocyclic peptide, which is very rare in the literature.

Strategies of C–H activation catalyzed by other transition metals have also been extensively applied to peptide chemistry. A representative of which is the manganese-catalyzed strategy pioneered by Ackermann and coworkers. As early as 2017, they reported an example of alkynylation based on Mn-catalyzed C–H activation and its successful application to peptide macrocyclization.¹²⁰ In 2019, they achieved the use of manganese-catalyzed hydroallylation for the modification of peptides, nucleotides, and drug molecules, as well as the macrocyclization of peptides, under mild and heteromerization-free reaction conditions.¹²¹ In 2021, they succeeded to use the propargyl ester reagent to install propiolate at multiple sites of the peptide more conveniently by using manganese catalytic activation and realized a variety of cyclized forms of the peptide¹²² (Scheme 18c). Moreover, C–H alkylation yielded an α,β -unsaturated ester, which could be subjected to further derivations. In 2023, Zheng and coworkers





Scheme 18 Selected peptide macrocyclization strategies *via* C–H activation on phenylalanine, tyrosine and tryptophan moieties. (a) & (c) C(sp₂)–H at tryptophan indole's C2 position with aryl halide and terminal alkyne, respectively; (b) C(sp₃)–H at alanine with aryl halide; (d) C(sp₂)–H at tryptophan indole's C7 position with maleimide.

reported a new rhodium-catalyzed macrocyclization strategy *via* late-stage maleimidation on C(7)–H tryptophan¹²³ (Scheme 18d). Notably, this catalytic system was not limited by the position of tryptophan in the polypeptide, while the maleimide introduced in the cyclic product could also be used as an effective click functional group to further modify the products.


3.5. Heteroatom arylation/alkylation-mediated cyclization

Although heteroatoms (e.g., N, O, and S), other than the amide bonds, do not exist in a large proportion in peptides, they often play critical roles in peptide chemistry and biochemistry. For example, disulfide bonds and thioether bonds can stabilize and regulate the secondary structure of peptides,^{31,51} and the role of diaryl ether facilitates the synthesis of many natural product peptides such as vancomycin.¹²⁴ The special nature of heteroatoms gives a special status to the natural amino acids containing these heteroatoms. In 2013, Harran and coworkers


developed a method for peptide macrocyclization based on the Tsuji–Trost reaction.¹²⁵ A common cinnamyl carbonate was attached to the peptide, and then $\text{Pd}(\text{PPh}_3)_4$ was used as a catalyst to selectively react it with the phenol sidechain of tyrosine on the unprotected peptide to obtain a cyclic peptide with cinnamyl ether bond (as cycloetherification or cinnamylation). In 2023, Zhao and coworkers developed the copper-catalyzed Shono-type oxidation of proline residues as a peptide macrocyclization strategy. This strategy used the intramolecular hydroxyl group as a nucleophile to synthesize challenging small-size cyclic peptides with high selectivity under mild reaction conditions; the protocol was easy to operate and well-tolerated different amino acids¹²⁶ (Scheme 19a). In 2021, Chen and coworkers obtained various medium to large-sized cyclic peptides linked in the form of biaryl thioethers *via* the chemoselective intramolecular *S*-arylation of thiols and iodobenzene catalyzed by palladium¹²⁷ (Scheme 19b). In 2024, Arisawa and coworkers reported a new strategy for the




(a)




(b)



(c)



(d)



Scheme 19 Selected peptide macrocyclization strategies via heteroatom arylations/alkylations: formations of (a) hemiaminal ethers; (b) biaryl ethers; and (c) dithioacetal; (d) tryptophan indole's N1 allylation.

rhodium-catalyzed oxidation of methanol to formaldehyde, converting an unprotected peptide containing two cysteine residues to the cyclic peptide methylene dithioacetals¹²⁸ (Scheme 19c). Many functional groups in this strategy were well tolerated, and the side-reactions could be suppressed by controlling the concentration of formaldehyde to keep it at a low level during the cyclization step.

The relatively poor nucleophilicity of amino groups compared to O- and S-groups also gives rise to less arylation or alkylation of amino groups in most previously mentioned

strategies. In 2023, Chen, Yudin and coworkers disclosed a widely applicable strategy based on the Ulman-type reaction catalyzed by copper.¹²⁹ The Cu-catalyzed formation of C(aryl)-O or C(aryl)-N bonds between aryl iodide and natural amino acids such as Trp, His, and Tyr residues in various combinations provided a variety of unique tension-bearable multi-joint scaffolds to modulate the backbone conformation of peptides in an unprecedented manner. In the same year, Xie and coworkers combined the use of gold catalysis and silver salts to accomplish the chemo/site-selective arylation of relatively inert

N-terminal primary amines (in the presence of other amino acid residues with nucleophilic sidechains).¹³⁰ DFT calculations provided insight that the silver cation can serve as a transient coordination mask of the more reactive reaction sites. In the case of macrocyclization, two bifunctional linkers, 2-iodobenzoyl chloride and 2-iodobenzaldehyde, were used in their work to form covalent bonds between the amide and amine sites of unprotected peptides, producing cyclic peptides with new aromatic backbone linkage. This strategy showed good biocompatibility and can be further extended to the field of peptide labeling and peptide stapling. In 2024, Xu, Wang, Sun and coworkers reported a rapid late-stage organocatalytic N–H allylation strategy for the indole moieties of tryptophan and Morita–Baylis–Hillman (MBH) carbonates under mild conditions¹³¹ (Scheme 19d). The reaction was amenable to both LPPS/SPPS and a new handle was installed for further bioconjugation. Through these methods, various linkers of different rigidity and functionalities can now be installed into macrocyclic peptides by design.

4. Biological macrocyclization strategies

Macrocyclic peptides were first serendipitously discovered in living organisms, where there must be sophisticated biosynthetic pathways for their productions for highly specific biofunctions. Given the recent advances and further understandings in life science and biotechnology (e.g., genetic engineering, enzymatic engineering, and biochemical engineering), scientists at the biology and chemistry interface can now know more about the mysterious macrocyclic peptide synthetic mechanisms, master the exquisite biosynthetic skills, and even manipulate whole microorganisms to generate unnatural peptide macrocycles. To date, there are two basic protocols to form macrocyclic peptides in nature, as follows: (a) *via* the ribosomal synthesis of mRNA for translation to afford linear peptide precursors for further modifications to cyclic peptide products by different enzymes and (b) *via* the actions of non-ribosomal peptide synthetase to form cyclic peptide products directly.¹³² The rational use of genetically modified and highly specific enzyme-catalyzed reactions is powerful strategies for cyclopeptide syntheses (despite unresolved limitations, e.g., low sequence specificity). Judicious employment of thermodynamically less stable substrates, co-solvents and additives, and alteration of the reaction pH/temperature can favor a shift in the reversible reaction equilibrium to the right product side. Recently, a wide variety of biosynthetic techniques has been developed, e.g., genetic codon reprogramming, display technology, and *in vitro* translation in genetically programmed cells, which not merely speed up the whole *de novo* design and macrocyclization processes, but also develop novel macrocyclic peptide scaffolds not easily or even impossibly secured by other approaches. Biosynthetic/biocatalytic approaches will emerge as powerful and frontier research in

peptide macrocyclization in the years to come. A few typical literature examples are selected and featured below.

4.1. Ribosomal synthesis and post-translational enzymatic cyclization

Ribosomally synthesized and post-translationally modified peptides (RiPPs) are named for a class of structurally complex peptidic natural products based on their structural and biosynthetic similarities. Their biosynthetic process has been described in detail by a long name, commencing the synthesis of a biosynthesis gene cluster (BGC) code, translating the gene code within the ribosome, and then synthesizing a linear precursor peptide for post-translational enzymatic modifications. In general, the precursor peptide contains three key regions, as follows: (i) the leader sequence (at the N-terminus, for recognition by post-translationally modifying enzymes, and later removed by proteolysis), (ii) the core sequence (the site to be targeted and modified to access the mature product), and (iii) follower sequence (sometimes additional recognition sequence exists at the C-terminus and will also be proteolytically removed upon RiPP maturation). The leader/follower signal sequences direct the entire precursor peptide to a specific intracellular compartment and the core sequence will be subjected to a series of modifications by post-translationally modifying enzymes. A considerable number of these classes of biologically active peptide natural products is macrocyclic structures.

Although precursor peptides contain only proteinogenic amino acids, some unnatural amino acids or even non-amino acid structures can be incorporated during the enzymatic modification steps. One example is the lanthipeptide family, a class of highly active antibacterial agents, where dehydrogenases are typically used to introduce dehydroalanine/dehydrobutyric acid (Dha/Dhb) in their structure. It can be further modified to form lanthionine (Lan), methyllanthionine (MeLan), lemon protein (Lab) and methyl lemon protein (MeLAB) motifs. As a hot research topic, thiopeptides can also be modified to form these motifs. In 2021, Wang and coworkers obtained cyclic peptides of 2-aminovinyl-cysteine (AviCys) and 2-aminovinyl-3-methylcysteine (AviMeCys) motifs by using a variety of enzymatic modifications.¹³³ In 2022, Mitchell and coworkers prepared diverse pyridine-based macrocyclic peptides (pyritides), with variations in their macrocycle sequence and size, from linear precursor peptides *via* a two-site recognition pathway and a key macrocyclase catalyzed [4+2] annulation.¹³⁴ Inspired by a biosynthetic strategy, in 2014, Fasan and coworkers used chemically selective reactions between cysteine-reactive unnatural amino acids (*O*-(2-bromoethyl)-tyrosine) and thiols, in combination with split intein-catalyzed protein splicing (for circular ligation), to secure spontaneously and post-translationally modified thioether-linked ribosomally synthesized cyclic peptides in a sidechain-to-sidechain manner in bacterial cells.¹³⁵

In the process of RiPP natural and artificial biosynthesis, a wide variety of enzymatic macrocyclization reactions has been discovered and strategically employed, including disulfide S–S



bond formation, head-to-tail (or sidechain) C–O/N lactonization/lactamization, and C–C/S bond formation,^{136,137} leading to cyclic peptides of significant structural and functional diversities.


4.2. Non-ribosomal synthesis and enzymatic cyclization

Non-ribosomal peptide synthetases (NRPS) are a large class of multifunctional enzymes that can produce peptides without the cellular ribosomal machinery and messenger RNA. Since Walsh and coworkers first demonstrated the significant potential of NRP cyclase, enzymatic catalysis for accessing cyclic peptide natural products and their related analogues has been greatly developed; the reaction types and mechanisms have been surveyed and discussed in detail in other reviews (Scheme 20).^{132,138} Previous cyclase catalysis necessitated a minimum peptide length (less than 10 amino acids). Recently, in 2023, Wakimoto and coworkers disclosed a streamlined chemoenzymatic method on a solid support,¹³⁹ where linear peptides were first linked to the resin through a C-terminal diol


ester, and then upon cleavage, the diol ester group underwent head-to-tail cyclization by SurE, a representative penicillin-binding protein-type thioesterase (PBP-type TE). Excellent conversion rates were achieved in cyclizing small size-peptides without epimerization.

4.3. Genetic programming-mediated cyclization

In 2009, Suga and coworkers published a pioneering work,¹⁴⁰ whose theoretical sources were reported by Kawakami and Aimoto in 2007,¹⁴¹ to apply reprogrammed genetic coding to express and integrate glycolic acid (HOG) into, through ribosomal synthesis, a peptide chain containing Cys-Pro-glycolic acid (C-P-HOG). Recombinant peptide deformylase (PDF) was used to remove the N-terminal formyl group, and methionine aminopeptidase (MAP) was used to cleave methionine to produce the free N-terminus of any desired amino acid. Subsequently, spontaneous rearrangement could generate the corresponding C-terminal diketopiperazine-thioester with the removal of HOG. The subsequent *N*-to-*S* acyl transfer of the free amine



Scheme 20 Production of cyclic NRP analogues with different bio-strategies. (a) Chemoenzymatic synthesis of NRPs where recombinant TE alone or with other enzymes is commonly used to catalyze the regiospecific macrocyclization of synthetic linear peptide precursors activated by an SNAC moiety. (b) Biocatalytic synthesis of NRP analogues from synthetic linear peptide precursors or simple building blocks using multifunctional NRPS modules alone or with other enzymes. (c) Cell-free protein synthesis (CFPS) systems and synthetic-bioinformatic natural products (syn-BNPs) approach for *in vitro* synthesis of NRP analogues. Illustration is adapted with permission from ref. 132.



Scheme 21 Suga's pioneering work on reprogrammed genetic coding to prepare cyclopeptides.¹⁴⁰

group with the thioester non-enzymatically formed a backbone cyclized peptide in the form of an amide bond (Scheme 21). This pioneering work allows the incorporation of unnatural amino acids into the expressed peptide to spontaneously generate macrocyclic peptides with different sequences, greatly expanding the applications of this powerful genetic code reprogramming.

Although the last two decades have witnessed great research progress in the biosynthesis of both genetically encoded and non-natural cyclic peptides, the conventional RiPP and NRP systems can hardly produce desired amino acid sequences. Given that intracellular translation or *in vitro* translation techniques based on genetic codes can produce various amino acid sequences on demand (as shown in the work by Chin and coworkers in 2022),¹⁴² unnatural amino acids can possibly be introduced into the final peptide product by genetic programming techniques, which will certainly open new biosynthetic avenues for macrocyclic peptides.

5. Macrocyclization strategies for polycyclic, interlocked, self-assembled and directed folded peptides

Macrocyclic peptides, which are comprised of two or more ring structures, are known as polycyclic peptides. Compared with their monocyclic counterparts, they demonstrate rigidity and well-defined conformation for better ligand preorganization, thereby exhibiting stronger target binding affinity and higher metabolic stability, where usually the larger their size, the more

outstanding these advantages. Polycyclization can greatly improve the cell membrane penetration ability and oral administration performance of peptides, which has become one of the important directions in the development of cyclic peptide therapeutics, as well as imaging agents and diagnostics.^{143,144} However, polycyclization reactions of peptides/peptidomimetics are far more complex transformations than the monocyclization versions, where the commonplace latter methodologies are usually not translationally suitable/compatible for the former. The significant challenges include achieving precise control of the reaction site-selectivity, extending the substrate scope and functional group tolerance, and realizing the desired conformation control of the resulting polycyclic peptides. At present, the preparation of most bicyclic and polycyclic systems depend on (a) the use of multifunctional handles to react with multiple natural/modified/unnatural amino acid side chains *via* the so-called stapling reactions, in both solution and solid phases and (b) several intramolecular orthogonal cascade reactions. Elegant and strategic literature works are exemplified and detailed in the following section. Here, the mutual reaction orthogonality of the reported polycyclization methods, paired with NCL cannot be overemphasized.

Alternatively, unlike most of the familiar molecular monocyclic and above-mentioned polycyclic peptides, a few novel higher-order peptidic macrocyclic structures are held together by mechanical bonds and weak non-covalent interactions, *e.g.*, (a) by intermolecular interlocking to form peptide (pseudo)-rotaxanes and catenanes and (b) by coordinating with metal ions to fold and form macrocyclic cages and self-assemblies.



They furnish novel definitions and examples for supramolecular higher-order macrocyclic peptide architectures beyond NCL. Typical examples are also selected and briefly described below.


5.1. Cascade/sequential reaction-mediated polycyclization

Successive multistep modification is a feasible and dominant strategy to obtain polycyclic peptides. A method had been employed by forming a thioether bond between cysteine and oxidized tryptophan residues to construct the first ring in amatoxin derivatives, and then successfully access bicyclic heptapeptides and decapeptides through the end-to-end connection of the peptide chain. Disulfide bonds, as easily accessible functional groups available for transformations, broadly exist indispensably in various functional proteins in nature.³² In 2004, Leatherbarrow and coworkers designed and synthesized a novel protease inhibitor.¹⁴⁵ The enzyme inhibitor is a butterfly-type bicyclic peptide containing disulfide bonds, which was synthesized by the mainchain cyclization of the protected precursor peptide, followed by oxidation of the two cysteine side chains within the cyclic peptide to form disulfide bonds after deprotection, resulting in bicyclization. Unlike previous enzyme inhibitors, this bicyclic peptidase inhibitor retained the biological properties of natural proteins well, while achieving a significant reduction in size. As mentioned in Section 2, in 2019, Li and coworkers used NCL to first form a

backbone-based macrocyclic peptide, and then OPA to connect amino groups at different positions with the thiol group at the junction of monocyclic ring to achieve bicyclization.⁵⁶ Perrin and coworkers synthesized an eight-membered monocyclic peptide with an amide linkage by conventional methods, and then modified it with OPA to create a bicyclic peptide scaffold⁵⁷ (Scheme 22a). With the report of an increasing number of macrocyclization strategies, the synergistic applications of different methods to produce polycyclic peptides start to become prevalent.


Regarding the sidechain-based bicyclization strategies, ruthenium-catalyzed ring-closing olefin metathesis (RCM) and tungsten-catalyzed ring-closing alkyne metathesis (RCAM) have been reported with certain orthogonality and can be cooperatively used to produce bicyclic peptides.⁹⁵ In 2016, Waldmann and coworkers chemically and regioselectively synthesized sidechain-to-sidechain bicyclic peptides using the orthogonal Mo-catalyzed ring-closing alkyne metathesis (RCAM) and Ru-catalyzed ring-closing olefin metathesis (RCM) systems, and the bicyclic peptide ligands modified by this strategy showed high affinity to the activated Rab GTPase⁹⁶ (Scheme 22b).

Alternatively, although the use of protective groups in the formation of disulfide bonds on cysteine-rich peptide chains can avoid the side-reactions of thiols, it is still difficult to precisely control the reaction site after removal of the protecting groups, especially when more than one disulfide bond




Scheme 22 Selected peptide polycyclization strategies via cascade/sequential reactions. (a) NCL with OPA; (b) RCM and RCAM.


(a)



(b)



(c)



Scheme 23 Selected peptide polycyclization strategies through: (a) stepwise site-selective disulfide bridging with photocleavable protective group of cysteine; and (b) and (c) Ugi-type peptide dimerization and double stapling.

needs to be formed. These unprotected thiols may lead to mispairing during folding. In 2023, Li and coworkers employed a photocleavable protection group to avoid the side reactions of the C-terminal cysteine and continuously form disulfide bonds in a one-pot manner¹⁴⁶ (Scheme 23a). Through this sidechain anchoring strategy, they successfully prepared the bicyclopeptide α -symbiont toxin Vc1.1 containing two pairs of disulfide bonds. Given that the biological activities of peptides are chiefly determined by their secondary structures, the formation of polycyclic peptides using the sidechain-to-sidechain stapling

approach has high potential to target currently intractable proteins.

Sequential reactions of the same mechanistic type can also be adopted to accomplish ordered polycyclization by some coincidence on a support. In 2022, Huc and coworkers reacted thiol and chloroacetamide to continuously and selectively form a polycyclic structure on the surface of an aromatic polyamide oligomeric helix with a fixed structure.¹⁴⁷ The selectivity of the reaction can be related to the ring size, where initially the nearest tryptophan binds to the surface reaction site of the




aromatic polyamide oligomeric helix, followed by the formation of the next smallest ring; up to four cyclic peptides of different sizes and shapes could be formed sequentially following the same reaction type. In addition, based on their previous work, Chen and coworkers took advantage of the anchoring effect of formaldehyde on amino groups, and used the three-component condensation reaction of primary amine, formaldehyde, and guanidine, under different anchoring combinations and spatial arrangement in the reaction sequence, to obtain different polycyclic peptide structures cross-linked by the six-membered tetrahydro-1,3 and 5-triazine (4-triazine or THT) linker.¹⁴⁸ This reaction used simple reagents to polycyclically modify peptides under relatively mild conditions, which had the advantages of high efficiency and versatility. In 2023, Wessjohann, Rivera and coworkers reported a strategy to construct bicyclic peptides using MCRs.¹⁴⁹ The first approach of multicomponent macrocyclization-dimerization involved the assembly of two interlinked β -rotors, where a double Ugi reaction took place for the binding (Scheme 23b). The second approach exploits the efficacy of Ugi macrocyclization on the resin to introduce functional groups, which are subsequently

used for macrolactonization, leading to a fused doubly-stapled topology (Scheme 23c).

5.2. Multifunctional/multivalent crosslinker-mediated polycyclization

Among the 20 naturally occurring amino acids, the thiol group in the cysteine sidechain is one of the few ideal reaction sites in which the macrocyclization strategy is not limited to the formation of a monocyclic ring. Due to the alkylation reaction of thiols, cross-linking agents of 1,3,5-tris(bromomethyl) benzene (TBMB) skeleton were first applied to the synthesis of polycyclic peptides,^{150–152} to avoid the non-specific modifications caused by excessive reagents. By tuning the electrophilicity, chemists continued to improve different thiol-reactive linkers, and several “trivalent-acceptors” have been developed, including 1,3,5-tris(bromomethyl)benzene (TBMB), *N,N',N''*-(benzene-1,3,5-triyl)-tris(2-bromoacetamide) (TBAB), 2,4,6-tris(bromomethyl)-1,3,5-triazine(TBMT), 1,1',1''-(1,3,5-triazinane-1,3,5-triyl)tris(2-bromoethan-1-one)(TATB), and 1,3,5-triacyloyl-1,3,5-triazinane (TATA)^{153,154} (Scheme 24a). By



Scheme 24 Selected peptide polymacrocyclization strategies with multivalent crosslinkers via nucleophilic substitution reactions. (a) Based on 2-bromoacetamides and acrylamides; (b) based on disulfide clickable electrophiles.

combining them with a mature phage display platform, researchers can take advantage of their high diversity for screening to more quickly identify the molecules that interact with the desired ligand. In 2018, Boeckler and coworkers developed a new thiol-specific coupling agent 1,3,5-tris((pyridin-2-yl disulfanyl)methyl)benzene (TPSMB)¹⁵⁵ from 1,3,5-tribromomethyl benzene. Unlike the classical trivalent linker, the bicyclic peptide produced could not only be linked by three disulfide bonds, but also be reduced and re-linearized under physiological conditions. In 2023, Jiang and coworkers innovated a reversible and exchangeable sidechain click stapling strategy in the form of disulfide bonds¹⁵⁶ (Scheme 24b). This strategy was realized first *via* the addition of phthalimide sulfonyl chloride with various commercially available diacetylene to yield a range of double/triple-site electrophiles in varying length and rigidity. Then, expeditious cross-linking happened between the cysteines of the unprotected N-terminal peptide and the triadduct electrophiles in an ambient atmosphere, with removal of the phthalimide. Eventually, a variety of stapled peptides of medium to large sizes was formed in the exchange of disulfide bonds. This novel crosslinking agent of alkyl backbone is easy to obtain, where its length and angle are adjustable, thereby possessing the very advantages of simplicity, rapidity, and flexibility.

Chemical modification approaches through arylation by introducing new moieties to regulate the structures and functions of different biomolecules have been being extensively explored.¹⁵⁷ In 2013, Pentelute and coworkers discovered the facile, room-temperature nucleophilic aromatic substitution chemistry between perfluoroaromatic molecules and the thiolate of cysteine as new NCL and even peptide stapling tactics.¹⁵⁸ Since then, a variety of multifunctional crosslinkers with high efficiency and precise control of the reaction sites has been developed based on thiol arylations, in particular in the field of peptide poly-macrocyclization.

In 2017, upon detailed investigation of 2,3,5,6-tetrafluoroterephthalonitrile (4F-2CN) to selectively react with four thiolates of sequentially varied reactivity under mild aqueous conditions through nucleophilic aromatic substitution, Wu and coworkers strategically developed the precisely regulated and efficient locking (PROP-locking) tactic and transformed an unprotected linear peptide containing two cysteine (one from the N-terminal cysteine) and two penicillamine motifs (of different thiol nucleophilicity) into a tricyclic topologies through a one-pot double stapling protocol according to the kinetic sequence of nucleophilic attack¹⁵⁹ (Scheme 25a). Notably, the order of aryl C–S and C–N bond formation could be manipulated by the selective substitution of two non-N-terminal thiols of penicillamine.¹⁶⁰ In 2018, Pentelute and coworkers reported two methods of cysteine perfluoroarylation chemistry for the synthesis of arginine-rich bicyclic peptides, *i.e.*, by double stapling the thiols in the cysteine sidechain with a decafluorodiphenyl moiety and cross-linking three decafluoroaryl groups with one end already attached to the thiol of a peptide chain with the trivalent 1,3,5-benzenetriothiol¹⁶¹ (Scheme 25b). In 2023, Giuntini, Coxon and coworkers


introduced (5,10,15,20-tetrakis(pentafluorophenyl)porphyrin as a platform crosslinker for the synthesis of polycyclic peptides¹⁶² (Scheme 25c). This crosslinker allowed the direct modification of unprotected linear peptides containing multiple cysteines under physiological conditions, with the peptides containing two cysteine residues readily stitching by side-chains; or stepwise modifications by subsequently introducing a second peptide in the same manner to obtain bicyclic structures. Similarly, long peptides with more than two cysteine residues could furnish polycyclic products containing up to three peptide “loops”. In 2024, Xu and coworkers presented the first site-selective unsymmetric perfluoroaryl stapling protocol for Ser and Cys residues in unprotected peptides *via* visible-light-induced radical defluorinating perfluoroarylation, and then S_NAr under mild conditions with a high reaction rate; further late-stage functionalization of the resulting stapled peptides was feasible, paving new ways for potential polycyclization.¹⁶³

In addition to polyfluoroaryl multifunctional crosslinkers, the strategy of using iodoaryl reagents for peptide polycyclization was reported by Chen and coworkers in 2021¹⁶⁴ (Scheme 26a). They demonstrated great versatility and efficiency for the selective macrocyclization and polycyclization of native unprotected peptides under mild conditions using a variety of readily available diiodine and triiodoaromatic reagents with different aromatic and heteroaromatic cores by the palladium(II)-catalyzed arylation of cysteine residues. In 2021, Spokony and coworkers reported the use of trivalent gold(III)-based reagents for transition metal-mediated arylation reactions to produce bicyclopeptides¹⁶⁵ (Scheme 26a). The metal complexes used in this strategy were easy to synthesize, while the products did not require purification, even allowing rapid reactions with peptides under phage-compatible conditions. In 2022, Mudd and coworkers synthesized and explored the scope and generality of four new trivalent gold(III) complexes in the construction of bicyclic peptides¹⁶⁶ (Scheme 26a).

Bismuth metal is a special element with low biological toxicity, which can also bind with the cysteine residues in glutathione, peptides and proteins.^{167,168} Inspired by this, Nitsche and coworkers pioneered a novel metal coordination strategy to generate a bicyclic peptide employing a linear precursor peptide with three cysteine residues and a bismuth(III) salt¹⁶⁹ (Scheme 26b). Under physiological conditions, a high concentration of bismuth tribromide in DMSO solution was added directly to the aqueous peptide solution, paired with an excess of thiol-free reducing agent tris(2-carboxethyl) phosphate (TCEP) during the process for ensuring complete reduction of all the cysteine residues. Due to the sulfrophilic property of the trivalent bismuth, the reaction was highly selective and fast to produce stable bicyclic Bi(III)-stapled peptides, which exhibited superior bioactivities, *e.g.*, entering cells through endocytosis in most cases and low toxicity. These bismuth bicyclopeptides offer new blueprints for the future development of cell-penetrating cyclic peptides and bismuth-containing therapeutics.¹⁷⁰

Since crosslinkers with two orthogonal reactive functional groups have been successfully designed and synthesized,






Scheme 25 Selected peptide polycyclization strategies with multivalent crosslinkers *via* nucleophilic aromatic substitution reactions. (a) Between 2,3,5,6-tetrafluoroterephthalonitrile and cysteines/penicillamines; (b) between decafluorodiphenyl moieties and cysteines; (c) between (5,10,15,20-tetrakis(pentafluorophenyl)porphyrins and cysteines. Illustration of (c) is adapted with permission from ref. 162.


Derda and coworkers introduced tridentate *C*2-symmetric light-responsive hydroxyl amine and di-chlorobenzene containing azobenzene (HADCAz) linkers for broad-scope peptide poly-macrocyclization¹⁷¹ (Scheme 26c). These linkers could be linked to the N-terminal serine and two cysteine

sidechains of the linear unprotected peptide in one-pot to form a “double-loop” structure. Interestingly, the linker could also be photo-regulated by reversibly converting between the *trans* and the *cis* form under blue light (365 nm) irradiation.


(a)



(b)



(c)




Scheme 26 Selected peptide polycyclization strategies: (a) via organometallic catalysts/reagents; (b) through metal coordination; (c) with multifunctional crosslinkers containing a photoswitch moiety.

A general method for tetracyclic peptide synthesis through the CEPS/CLIPS/CuAAC (“triple-C”) locking methodology was reported by Nuijens, Timmerman and coworkers¹⁷² (Scheme 27a). The specific approach was to first use the peptidase variant omniligase-1 (CEPS). The precursor peptide containing two cysteines and two azido-homoalanines (Aha) was initially subjected to head-to-tail enzymatic cyclization, followed by intramolecular polycyclization using a tetravalent crosslinker containing two bromomethyl groups and two alkyne functions by stepwise CLIPS bicyclization (double nucleophilic substitutions) and CuAAC (double click reactions). Later, Maarseveen and coworkers further modified a tetravalent crosslinker scaffold to embrace two active primary bromides with an aldehyde or


an aminoxy group,¹⁷³ using a combination of CEPS, CLIPS, and oxime ligation to generate a tetracyclic peptide from similar unprotected precursors (Scheme 27b). In 2023, Gao and coworkers reported two classes of multifunctional chloroxime-based crosslinkers for their cysteine-directed proximity-driven strategy (*i.e.*, first rapid cysteine labeling, and then proximity-driven amine-selective cyclization) to construct bicyclic peptides.¹⁷⁴ This crosslinker enabled different combinations of thiol and amino ligation, including terminal amino-Cys-Cys, Cys-Lys-Cys, and Lys-Cys-Lys. Another chloroxime-based, boronic acid-containing DCA-RMR1 crosslinker triggered the bicyclization of natural peptides through N-terminal amino-Cys-Cys double stapling¹⁷⁵ (Scheme 27b).



(a)



(b)




Scheme 27 Selected peptide polycyclization strategies with (a) stepwise multimodal transformations and (b) multifunctional chloroxime-based crosslinkers.

5.3. Unnatural/modified amino acid-mediated polycyclization

Multifunctional coupling approaches for sidechain stapling, such as the 1,4-dinitroimidazole reagent developed by Wang and coworkers,⁶⁴ and the on-resin dipyrrom construction by Chan, Long, Wong and coworkers,⁶⁵ upon modifying the side-chains of amino acids, furnished novel bicyclic peptide structures (Scheme 9c). Albericio, Lavilla, and coworkers exploited

diiodo-tyrosine in the peptide sequences and cyclized them with two tryptophans through C-H activation stapling to obtain doubly-stapled peptides¹⁰⁹ (Scheme 28a). In 2022, Nitsche and coworkers developed a general bicyclization strategy based on the condensation reaction between two 1,2-aminothiols (to be installed at both C/N-termini) and an unnatural amino acid containing a 2,6-dicyanopyridine (DCP) sidechain (in the



Scheme 28 Selected representative peptide bicyclization strategies using unnatural/modified amino acids. (a) Between diiodo-tryosine and tryptophan indoles' C2 position; (b) between 2,6-dicyanopyridine and terminal 1,2-aminothiols; (c) between Cys/Trp/indole-attached Lysine and Lys/Orn/Dap.

middle of the peptide sequence)¹⁷⁶ (Scheme 28b). Complex and rigid bicyclopeptides were synthesized selectively and biocompatibly. In 2024, Waser and coworkers developed a novel bivalent hypervalent iodine reagent, ethynylbenziodoxoles (EBxs), which could serve as a rigid staple to modify the amino sidechain of Lys/Orn/Dap, and then react with Cys/Trp/indole-attached Lys residues for peptide macrocyclization; this protocol was also found to be SPPS-compatible, and even orthogonal to HATU- lactamization to accomplish bicyclization in one-pot¹⁷⁷ (Scheme 28c).


5.4. Mechanically interlocked cyclization

With the continuous development of supramolecular chemistry, mechanically interlocked molecules such as rotaxanes and catenanes are widely used in materials science, catalysis, biology, and many other fields.¹⁷⁸⁻¹⁸¹ In fact, mechanical interlocking occurs naturally in DNA and protein molecules, such as lasso structures¹⁸² and molecular knots.¹⁸³ Despite the many difficulties in their synthesis, purification, and characterization, mechanical interlocking peptides can still be synthesized by researchers. The first synthesis of benzamide peptide rotaxanes was reported by Leigh and coworkers in 1999.¹⁸⁴ This strategy required the pre-design and synthesis of an axis derived from a short peptide, followed by the formation of a ring around the axis relying on intermolecular hydrogen bond orientation in a low-polar solvent. Since then, different


peptidorotaxanes had been successively reported using similar strategies.¹⁸⁵⁻¹⁸⁸ In 2006, Leigh and coworkers studied the strategy of re-encapsulation of the axis through the peptide ring to synthesize peptidorotaxanes.¹⁸⁹ In 2007, Dawson and coworkers selectively and efficiently formed peptidorotaxanes by crossing linear thioester peptides through a cyclic peptide, which could subsequently be cyclized using NCL ring-closure to afford bicyclic interlocked² heterocycles¹⁹⁰ (Scheme 29a). Early synthetic strategies demonstrated the synthetic accessibility of mechanically bonded interlocked peptides as well as their unique functions and properties. Although amino acid sequences have been introduced into these mechanically interlocked structural molecules for a long period, the key macrocyclization steps are still accomplished by the reactions of non-peptide prefunctionalized components,¹⁹¹ and mechanically interlocked holopeptide structures are still difficult to obtain by purely chemical synthesis. In 2024, Numata and coworkers disclosed the first synthesis of an all-peptide-based rotaxane from a proline-containing cyclic peptide¹⁹² (Scheme 29b).

Lariat peptides are a class of naturally occurring mechanical interlocking peptides, which are attractive for next-generation antibiotic development. Currently, the combination of gene mutation technology and site-selective chemical modification is the best strategy for the rational design and synthesis of lasso peptides¹⁹³ (Scheme 29c). Several investigators have provided some excellent strategies in the chemical synthesis of lariat


(a)



(b)



(c)



Scheme 29 Selected natural and synthetic examples of peptide-based (a) & (c) catenanes and (b) rotaxanes. The illustrations of (a) and (c) are adapted from ref. 190,193, respectively, and (b) ref. 192, with permission.

peptides.^{194,195} Indeed, the full chemical synthesis of natural lasso peptides remains an elusive goal. However, these topologically extraordinary building blocks can be employed to construct a range of interlocked molecular structures. In 2016, Link and coworkers reasoned the use of loop-cleaved lasso peptides as building blocks to create peptidic catenanes. After the mutagenesis of the lasso peptide microcin J25 (MccJ25) with two cysteine residues followed by trypsin cleavage, the

[2]rotaxane structure was obtained, where it could further self-assemble into a [3]catenane and [4]catenanes by multimerization through the disulfide linkage at room temperature in aqueous solution.¹⁹⁶ Inspired by this surprising discovery, in 2021, they used genetic recombination technology to change the quantity and position of cysteine in the molecular structure of MccJ25, predetermining the building block structure produced after enzymatic cleavage. A range of different mechanical


interlocking peptides was generated in water *via* the covalent self-assembly of different building blocks under mild conditions, including rotaxanes, daisy chains, catenanes, and double-lasso macrocycles.¹⁹⁷ In 2021, Ma and coworkers successfully expressed the lariat peptide biosynthesis gene cluster *stla* with systematic site-directed mutagenesis on the precursor peptide-encoding gene based on a marine *Streptomyces* heterologous expression system, generating 17 stlassin derivatives and expanding the diversity of lariat peptides.

5.5. Metal-directed stapling, folding and self-assembly

In addition to covalent bonding, the metal ion coordination approach can also provide alternative strategies for accessing structural restricted macrocyclic peptides. In 2014, Fei and coworkers published a peptide stapling strategy based on iridium-(III)-bis(histidine) chelation (Ir-HH cyclization).¹⁹⁸ By reacting the Ir(III) complex bis(2-phenylpyridine-C2,N)-bis(aquo)iridium(III) trifluoromethanesulfonate with different model peptide ligands containing two unprotected histidine residues at different positions, various structurally constrained stapled metallopeptides were formed with excellent luminescence imaging capabilities (Scheme 30a). In 2023, similar cyclic ruthenium-peptide conjugates were reported by Sun, Bonnet and coworkers¹⁹⁴ (Scheme 30b). By direct coordination coupling of the chiral ruthenium anticancer warhead Λ/Δ -[Ru(Ph₂phen)₂(OH₂)₂]²⁺ to histidine and methionine residues

containing the RGD peptide sequence, Ac-MRGDH-NH₂, two dimeric isomers of the cyclic ruthenium-peptide complexes, Λ -[1]Cl₂ and Δ -[1]Cl₂ were created, respectively, which could function as potential brain tumor-targeted phototherapeutic prodrugs. In 2023, Arndt and coworkers took advantage of the surprising affinity of methanobactin OB3b (Mbn-OB3b) for copper ions ($K_a \approx \text{Cu(I)} 1034$) to generate a conjugated heterocyclic system through a cyclic dehydration-sulfurization procedure.¹⁹⁵ As a templated total synthesis example, Cu(I)-bound methanobactin OB3b with a caged structure was obtained, which is another important application of metal ion coordination in peptide chemistry.

Since short helical peptides were shown to be outstanding building blocks for diverse supramolecular nanostructures, in 2014, Sawada, Fujita, and coworkers proposed a new artificial nano-assembly method for silver(I) and short peptide helices, Gly-Pro-Pro, to obtain a nanosized channel,¹⁹⁹ upon the introduction of two terminal pyridines for Ag(I) binding. An ethanol solution of this modified peptide linker was slowly diffused into an aqueous solution of AgBF₄ (56 mm) at 108 °C for one week. The transient folding conformation during the metal-driven assembly process stabilized the peptide-folded porous crystal. Generally, this is the first folding and self-assembly (F&A) strategy for the construction of well-defined peptide-based nanostructures. Later, these authors employed different sequences of short peptides with pyridine–silver ion binding,



Scheme 30 Selected representative cyclic metal-peptide complexes and higher-order self-assembled cyclic metal-peptide nanostructures. (a) & (b) Iridium and ruthenium-chelated stapled peptides; (c) metal ions-directed folding and assembly of short peptide ligands. Illustration of (c) is adapted with permission from ref. 200.



simultaneously carrying out orthogonal folding and self-assembly processes to obtain a variety of highly entangled metal-peptide frameworks, as well as catenanes²⁰⁰ (Scheme 30c).

6. Technical aspects of peptide macrocyclization strategies

6.1. Comparisons of peptide macrocyclization strategies

Over the past two decades, extensive painstaking efforts have been devoted to exploring the synthesis and applications of macrocyclic peptide compounds, and a variety of strategies has been developed for the preparation of peptidic macrocycles. Ideally, their synthetic protocols should be simple and efficient, highly specific, and probably “traceless” and fully compatible for any amino acid sequence. However, due to the intrinsic differences in the properties of each amino acid, being natural or non-canonical, and the limitations of the current level of science and technology, achieving the ideal macrocyclization reaction for peptide and peptidomimetics is difficult and there is still a long way to go. Despite the dramatic recent advancements, many reported macrocyclization methods still suffer from side-reactions (e.g., isomerization, oligomerization, and epimerization), limited substrate scope, and low yields. In addition, there are many synthetic difficulties, high costs, and environmental issues, *i.e.*, non-sustainability.²⁰¹ Here, we summarize the different strategies for peptide macrocyclization (Table 1), each of which has significant advantages and obvious limitations. The key to choosing the best macrocyclization strategy is based on the targeted components and applications of the cyclic peptide products.

6.2. Comparisons and remarks for macrocyclic peptide synthesis methods

To date, peptide synthesis technology can be categorized as (i) natural extraction, (ii) chemical synthesis, and (iii) biosynthesis. Chemical synthesis can be further divided into liquid-

phase and solid-phase synthesis, where the main difference is whether a solid resin is used. Natural extraction can be regarded as the early form of biosynthesis. In recent years, with the development of biotechnology and genetic engineering, artificially controlled biosynthetic methods have been developed. Biological enzyme catalysis and gene recombination techniques have also been used to synthesize both linear and cyclic peptide products.

6.2.1. Liquid-phase peptide synthesis (LPPS). Liquid-phase synthesis is an early, well-established method for peptide synthesis, which can be divided into two ways, as follows: (1) linear synthesis: usually starting from the C terminus (the carboxylic acid group) of the polypeptide chain and introducing a protective group (such as Fmoc or Boc) to protect the N terminus (the amine group). An active group (such as an active ester and an acyl chloride) is introduced to the protected amino acids and coupling reactions iteratively occur between the carboxylic acid group and the previous amine group, or *vice versa*. Simply, this process is the wash-deprotection-wash-introduction of the protected amino acid and repeated, thereby elongating the peptide chain on demand. (2) Fragment synthesis method: each desired peptide fragment is synthesized first, and then each fragment is condensed to synthesize the target polypeptide. As a classical example, the NCL-based protocol to chemically synthesize peptides and proteins was reported by Kent and coworkers in 1994.¹⁰

Although the synthesis and modification of long-chain peptides have been gradually replaced by the solid-phase method, many peptide macrocyclization reactions are still carried out in the liquid phase. Given that the ends of the chain-like precursor peptide in the liquid phase are unconstrained and maintain a high degree of conformational freedom, it has certain advantages in backbone cyclization and sidechain stapling with external components. Regarding the selection of solvents, ranging from their compatibility with physiological conditions to the aspects of cost and environmental protection, water is the best priority choice. For instance, NCL¹¹ and the D-A⁶⁴

Table 1 Comparison of various peptide macrocyclization strategies

	Chemoselectivity	Regioselectivity	Advantages	Limitations
Non-catalytic chemical strategies	Based on the intrinsic/special reactivity of amino acid sidechains	Based on selective deprotection; the distance between reaction sites	The reaction conditions are mild; natural peptides can be modified	Only limited natural amino acids can serve as reaction sites; use of unnatural amino acids
Catalytic chemical strategies	By selectively activating the organic fragments involved in the reaction by the catalyst in use	By controlling the number of amino acids and structures that can participate in the reaction	High cyclization efficiency; good versatility; no excessive requirements in amino acid sequence and composition	Metal ion leaching from the catalyst is costly/difficult to remove; high-loading metal catalysts are expensive
Biological strategies	Based on enzymatic recognition of amino acid sequence; expression of genetic factors		Good selectivity and biocompatibility	The design and acquisition of artificial enzymes are difficult and costly
Polycyclic strategies	Based on orthogonality of various methods; special reactivity of amino acid side chain	By orthogonal protection; limiting the number of reaction sites; pre-functionalizing reaction handles	The molecular configuration & conformation can be more restricted & tailored	The threshold is higher and limited methods available
Supramolecular strategies	Based on mechanical bonds; metal coordination; intermolecular noncovalent interactions		Moving from the chaos to order increases the application potential of peptides, which can be controlled by fine-tuning the structures	At present, it is still necessary to complete the key macrocyclization steps by introducing a large number of non-peptide structures



strategies for peptide macrocyclization had been conducted in aqueous media. However, many hydrophobic amino acids (isoleucine, leucine, valine, *etc.*) or polypeptides with a large molecular weight will suffer from poor solubility or even insolubility in water. Therefore, it is necessary to use mixed or organic solvents to enhance the solubility of the precursor peptides for reacting with other reaction components. In addition, it is necessary to consider whether the polarity of the solvent matches, which will lead to side-reactions and the practical feasibility of the operation. The common solvents for LPPS include DMF, DMSO, water, and mixed THF/MeCN/MeOH solvent system.

In short, the liquid-phase synthesis of cyclic peptides usually requires mild conditions to avoid damaging their sensitive functional groups. Besides, the macrocyclization reaction in the liquid phase usually needs to be carried out at a low concentration (otherwise called high dilution) to reduce the occurrence of oligomerization, isomerization, and many other side-reactions, which will indirectly lead to a reduction in the reaction efficiency, the difficulty of purification, and solvent waste.

6.2.2. Solid-phase peptide synthesis (SPPS). The standard procedure for solid-phase peptide synthesis is to pre-immobilize the C-terminus of the first N-terminal protected (mainly Fmoc or Boc) amino acid onto an insoluble solid resin support, and next couple the deprotected N-terminus of the amino acid with the second amino acid whose carboxylic acid group has been activated *via* a condensation reaction. This procedure is operated and repeated (*i.e.*, condensation → wash → deprotection → wash → next round of condensation) until the desired length of the peptide chain is reached. Finally, all the protecting groups are globally removed, and the peptide is separated from the resin for further HPLC purification. SPPS can synthesize longer and more complex peptides than LPPS. However, for excessively long peptides, it is still necessary to combine it with liquid-phase fragment synthesis to achieve the synthesis of more than 60 amino acid peptide chains.

The problems that should be given attention when using the solid-phase synthesis method are as follows: (i) the selection of a protective base, (ii) the type of resin, and (iii) the condition of peptide cleavage. In the selection of protecting groups, the Fmoc protective group is preferred in conventional synthesis. Fmoc is relatively easy to remove under alkaline conditions and is relatively stable under acidic conditions. It also has a certain orthogonality with most other amino acid-protecting groups under acidic conditions. Hence, the use of Fmoc protection is more flexible in the choice of synthetic conditions. Another common protecting group, Boc, typically requires deprotection under conditions of strong acids such as TFA and is not suitable for scenarios where reuse is required. It is usually used as a supplement to Fmoc protection. Most of the other amino acids also have their own featured protecting groups. In fact, the choice of resin is more diverse, not only the resin materials are different, but also the linkers used to attach amino acids to the resin beads are different. In recent years, polystyrene core resin linkers have been most widely used. As shown in Fig. 3,

resins with different linkers have specific cleavage conditions, and different amino acid residues are obtained from the synthetic peptide after separation.²⁰²

Based on the pseudo-dilution effect in solid-phase synthesis, the solid-phase synthesis method is very beneficial for intramolecular cyclization. There have been many examples of cyclization on resins, such as macrocyclization of thiol-ene reactions,⁴² click reactions,²⁰³ and ring-closing olefin metathesis.¹¹⁰ In addition, macrocyclization between molecules can also be achieved by adding excess external components such as in glacier coupling,²⁰⁴ Ugi reaction,⁷⁰ and other cross-coupling strategies.²⁰⁵ Compared with the liquid-phase synthesis method, the solid-phase synthesis method largely avoids the problem of oligomerization of peptides due to the combination of the precursor peptides and resin. Moreover, the solid-phase synthesis method is easy to apply (*i.e.*, high yield and high purity), and has developed into an important tool for the chemical synthesis of peptides. Unfortunately, solid-phase synthesis is generally less economical and requires further improvements in efficiency and sustainability for industrial mass production.

6.3. Characterization and computational analysis

For the development of macrocyclic peptides, monitoring and characterization are the key to their successful synthesis. Therefore, the processes of elongation, modification, and cyclization of polypeptide chains are examined by a variety of methods. Peptide synthesis is usually achieved by solid-phase synthesis. The detection of reaction completeness of peptide chain extension can be performed by detecting the primary and secondary amines by the Kaiser test (Ninhydrin test) and chloranil test (acetaldehyde test), respectively. This detection of incomplete precursor peptides requires separation from the resin by reversed-phase high-performance liquid chromatography (HPLC) to calculate the yield, and mass spectrometry (ESI) to determine the molecular weight to assist qualitative analysis. In the case of shorter peptide chains, proton and carbon nuclear magnetic resonance spectroscopy (¹H and ¹³C-NMR) can also be used to detect the type and number of hydrogen atoms and carbon atoms in different chemical environments for qualitative analysis, respectively. Generally, completion of the cyclization step is accompanied by a change in molecular weight, and the detection of this process can also be preliminarily judged using a combination of HPLC separation and mass spectrometry detection. Regarding some macrocyclization methods, when the cyclic peptide products are not suitable for mass spectrometry analysis or have no molecular weight difference from the precursor peptide (such as azide–alkyne cycloaddition), Fourier transform infrared spectroscopy (FTIR) can also be used to detect the appearance or disappearance of the characteristic peaks of different functional groups.

In the case of more complex structures of cyclic peptides, X-ray crystallography can provide more information on their molecular structure including atomic arrangement and spatial structure. However, there are many challenges associated with the X-ray crystallography of cyclic peptides, especially the



Resin name	Cleavage conditions	Peptide product	Resin structure
Wang resin	90-95% TFA in CH_2Cl_2 1-2 h	Acid	
Rink acid resin	1-5% TFA in CH_2Cl_2 5-15 min or 10% AcOH in CH_2Cl_2 , 2 h	Acid	
HMPB resin	1% TFA in CH_2Cl_2 2-5 min	Acid	
2-Chlorotriyl chloride resin	1-5% TFA in CH_2Cl_2 1 min	Acid	
SASRIN resin	1% TFA in CH_2Cl_2 5-10 min	Acid	
Rink amide resin	50% TFA in CH_2Cl_2 1 h	Amide	
MBHA resin	HF 0°C, 1 h	Amide	
Hydrazine resin	$\text{Cu}(\text{OAc})_2$, pyridine, acetic acid, nucleophile in CH_2Cl_2 or THF	Acid, ester, amide	

Fig. 3 Summary of representative resin structures with their corresponding cleavage conditions and cleavage products.

challenging crystallization of cyclic peptides with larger molecular weights and conformational flexibility. Simultaneously, more difficulties will be encountered in the resolution of their

structure because of the complexity of their molecular structure. More often, researchers choose to use other means of representation. For example, the secondary structure of cyclic



peptide products (α -helix, β -fold, random coil, *etc.*) can usually be analyzed by circular dichroism (CD) spectroscopy. CD spectroscopy has high sensitivity in the detection of molecular chiral structure and structural changes. Two-dimensional (2D) NMR can also be widely applied in the analysis of cyclic peptide structures, including NOESY spectrum (detecting the spatial relationship between different residues in the ring); COSY spectrum (the interaction between adjacent amino acid residues); TOCSY spectrum (establishing the interaction network between amino acid residues in the whole molecule to resolve the overall structure); and HSQC spectrum (directly detects the interaction between hydrogen atoms and neighboring nuclei, assisting in determining the carbon spectrum information). The characterization of the tertiary structure of cyclic peptides, including hydrogen bonds, ionic bonds, and hydrophobic interactions, requires a combination of X-ray crystallography, high-resolution mass spectrometry, high-throughput sequencing, and advanced structural biology techniques.

Various peptide-based frameworks/polymers formed by self-assembly of short peptides with metals and cyclic peptide-based nanostructures held through intermolecular forces usually possess three-dimensional regularly arranged crystal structures. Therefore, for the characterization and analysis of these compounds, both solution/solid-state nuclear magnetic resonance spectroscopy can be used to detect their structural information and X-ray diffraction can be used to obtain their detailed crystal structure information. Simultaneously, the morphology and microstructure of the materials can be observed and characterized by scanning electron microscopy (SEM). In the case of more complex peptidic macrocycles, different levels of detection methods are needed to complement each other and comprehensively analyze their compositions and structures.

The three-dimensional conformation of cyclic peptides is closely related to their molecular properties. However, the network of interacting structural elements in macrocyclic peptides generates conformational organization that is challenging to predict and characterize. As the ring size increases, the conformational-activity relationship of the ring molecule becomes complicated. Indeed, cyclic peptide molecules still exhibit some flexibility, with multiple conformations prevalent in solution. These metastable conformations are usually difficult to observe and isolate directly by existing means, which was named by Yudin and coworkers “dark conformational space”.²⁰⁶ Although the presence of the chameleon effect is thought to be one of the reasons for the improved membrane permeability, little is known about the transition between these conformations in reality. Therefore, it is necessary to improve our structural understanding of cyclic peptides to determine or predict their molecular structure and properties. In recent years, conformational studies of a variety of cyclic peptides have been reported. Lokey and coworkers developed a method to elucidate the conformation of cyclic peptides in solution using NMR in combination with density functional theory (DFT) and molecular dynamics (MD) calculations.²⁰⁷ The nearly exhaustive backbone sampling, sequence design, and energy

landscape calculation by Hosseinzadeh, Bhardwaj, Mulligan, and coworkers enumerated stable structures that could be adopted by macrocyclic peptides composed of L-and D-amino acids. Over 200 possible structures were computationally designed and predicted to fold into a single stable structure.²⁰⁸ Lin and coworkers, using MD simulation results, trained machine learning models to predict the structure of cyclic peptides.²⁰⁹ In 2023, Ovchinnikov, Bhardwaj and coworkers reported the use of AlphaFold and RoseTTAFold for the structure prediction and design of cyclic peptides.²¹⁰ Deep learning techniques based on huge databases provide considerable opportunities for the structure prediction and design of biomolecules such as cyclic peptides. Establishing a huge database to analyze and predict the structure of cyclic peptide molecules, as well as probably various peptide-based metal frameworks/polymers/supramolecules/nanomaterials through deep learning, holds tremendous promise in the coming future and is a milestone in this field. However, at present, the comprehensive simulation of cyclic peptides is still in the initial stage of development, and the establishment of each data library is only available for the algorithm prediction of a single specific structure or type of cyclic peptide.^{211,212} Thus, there is still a large number of tasks to be completed to realize huge and comprehensive knowledge networks.

7. Summary and outlook

The structural diversity, stability, and modularity of cyclic peptides (Fig. 4) make them excellent compounds for generating self-assembling materials with exceptional properties for use as therapeutic drugs. In the last decade, bioactive and functional cyclic peptides have been continuously reported, and peptide macrocyclization strategies, other than lactamization and NCL, have been greatly enriched. However, most of them are limited by the presence of certain natural/unnatural amino acids with specific functional groups and specific sequences. The ultimate goal of precise macrocyclization with arbitrary amino acids or arbitrary amino acid sequences is still a long way off. In essence, there are very few literature-reported methods that are expected to achieve potential translational, industrial-scale production, given that most either incur significant economic costs or are environmentally unfriendly. Therefore, more green, efficient, sustainable, and controllable macrocyclization strategies need to be further designed and optimized.

Alternatively, how can the “right structure” be obtained and stabilized at the theoretical level? This is the most intuitive problem faced by the *de novo* design of cyclic peptides. In fact, secondary structures such as hydrophobic cores or helices and β -sheets other than the β -hairpin are difficult to obtain for small-sized cyclic peptides, and cyclic peptides with larger molecular weights have a variety of conformations in solution. Designing peptide macrocycles with rigidity, high tension, and complex topology remains an unsolved but pressing fundamental challenge. At present, we have an insufficient






Fig. 4 Overview of synthetic strategies for different categories of peptidic macrocycles and their salient advantages compared with those of their simple linear counterparts. Illustrations of selected examples are adapted with permission from ref. 197, 199 and 213.


understanding of the correlations at the theoretical level such as “the correlation of chemical structure-spatial conformation-macroscopic properties”, and less structural information can be obtained, which makes it difficult to accurately predict the structure of macrocyclic peptides. Briefly, the current limited development of cyclic peptides is due to the inadequacy of macrocyclization methods and insufficient diversity of cyclic peptides.

Future exploration of non-ribosomal peptide synthetases (NRPS), a class of multifunctional enzymes, will be definitely highly promising. These enzymes have modular domains containing characteristic motifs, which include (i) the adenylation (A)-domain for substrate recognition and activation, (ii) peptidyl carrier protein PCP-domain (also known as thiolation (T) domain) for cellular transport to their respective catalytic locations, (iii) the condensation (C)-domain, which catalyzes the formation of peptide bonds, and (iv) thioesterase (TE)-domain (releasing the growing peptide through hydrolysis, oligomerization or cyclization) (Scheme 31). These enzymes can synthesize nonribosomal peptides by condensing amino acid sequences (transfer of the aminoacyl or peptidyl group), where this mechanism is very common in microorganisms.²¹⁴

Further evolution or engineering of these enzymes will adamantly give rise to unprecedented and unexpected results.

Regarding another interesting aspect, in 2022, Carreira and coworkers documented the first total syntheses of tricyclic mutanobactins A, B and D by employing a novel thiazepanone amino acid building block.²¹⁵ In 2024, Perrin and coworkers presented an interesting indole-based peptide stapling tactic by reacting 5-hydroxypyrroloindoline with either a cysteine-thiol or tryptophan-indole to yield the corresponding tryptathionine or 2,2'-bisindole-stapled peptides.²¹⁶

It is expected that with the progress of basic research on ring-closing metathesis^{217,218} and traditional strategies on complex macrocyclic suprastructure formation,^{219–221} more researchers will enter the field of peptide macrocyclization.²²² Automated continuous-flow synthesis has recently been reported for growing long-chained peptides, peptide-nucleic acid conjugates, and traditional cyclic peptides; alternatively, cyclic peptide structures start to be predictable and optimizable by deep learning. In the case of the structure and conformation prediction of new macrocyclic peptide scaffolds, more advanced programs/software with excellent and specific chemo/bio-informatics (such as AlphaFold and RoseTTAFold



Scheme 31 Non-ribosomal peptide synthesis (NRPS) modules composed of adenylation (A), thiolation (T) and condensation (C) domains with a terminal thioesterase (TE) domain. Illustration is adapted with permission from ref. 214.

for proteins) need to be invented. It is expected that these technologies will provide theoretical and technical support for ideal drug discovery and the development of “accurate prediction, efficient synthesis, and rapid screening” for cyclic peptides, paired with the development of novel and practical macrocyclization strategies for their synthesis, and hopefully

manufacturing. With global concerted research efforts from multidisciplinary experts, as well as the new blood in different areas, this highly dynamic, multidisciplinary and evolving research field of the synthesis of peptidic macrocycles and beyond (*i.e.*, their derivatives/hybrids/conjugates/variants/frameworks/self-assemblies/polymers), which is of paramount



importance, will and must be taken to next strata, with new drugs, new probes, new materials, and new tools, to resolve contemporary global scientific and societal challenges and the betterment of humankind.

Data availability

Data sharing is not applicable to this article as no datasets were generated or analysed during the current study.

Conflicts of interest

There is no competing interest to declare.

Acknowledgements

This work is partially supported by Hong Kong Baptist University (RMGS-2022-13-07). P. Fang and W.-L. Chan are grateful for Prof Yixin Lu's academic support from National University of Singapore.

References

- 1 K. Fosgerau and T. Hoffmann, *Drug Discovery Today*, 2015, **20**, 122–128.
- 2 A. Zorzi, K. Deyle and C. Heinis, *Curr. Opin. Chem. Biol.*, 2017, **38**, 24–29.
- 3 H. Y. Zhang and S. Y. Chen, *RSC Chem. Biol.*, 2022, **3**, 18–31.
- 4 C. Bechtler and C. Lamers, *RSC Med. Chem.*, 2021, **12**, 1325–1351.
- 5 T. A. F. Cardote and A. Ciulli, *ChemMedChem*, 2016, **11**, 787–794.
- 6 P. G. Dougherty, A. Sahni and D. Pei, *Chem. Rev.*, 2019, **119**, 10241–10287.
- 7 H. Shao, V. Adebomi, A. Bruce, M. Raj and K. N. Houk, *Angew. Chem., Int. Ed.*, 2023, **62**, e202307210.
- 8 A. A. Vinogradov, Y. Z. Yin and H. Suga, *J. Am. Chem. Soc.*, 2019, **141**, 4167–4181.
- 9 L. K. Buckton, M. N. Rahimi and S. R. McAlpine, *Chem. – Eur. J.*, 2021, **27**, 1487–1513.
- 10 P. E. Dawson, T. W. Muir, I. Clark-Lewis and S. B. H. Kent, *Science*, 1994, **266**, 776–779.
- 11 L. Zhang and J. P. Tam, *J. Am. Chem. Soc.*, 1997, **119**, 2363–2370.
- 12 J. P. Tam, Y. Lu and Q. Yu, *J. Am. Chem. Soc.*, 1999, **121**, 4316–4324.
- 13 V. Agouridas, O. E. Mahdi, V. Diemer, M. Cargoet, J.-C. M. Monbaliu and O. Melnyk, *Chem. Rev.*, 2019, **119**, 7328–7443.
- 14 J. A. Camarero, G. J. Cotton, A. Adeva and T. W. Muir, *J. Pept. Res.*, 1998, **51**, 303–316.
- 15 J. Tulla-Puche and G. Barany, *J. Org. Chem.*, 2004, **69**, 4101–4107.
- 16 B. H. Gless and C. A. Olsen, *J. Org. Chem.*, 2018, **83**, 10525–10534.
- 17 L. R. Malins and R. J. Payne, *Aust. J. Chem.*, 2015, **68**, 521–537.
- 18 Q. Wan and S. J. Danishefsky, *Angew. Chem., Int. Ed.*, 2007, **46**, 9248–9252.
- 19 R. Quaderer and D. Hilvert, *Chem. Commun.*, 2002, 2620–2621.
- 20 A. C. Conibear, E. E. Watson, R. J. Payne and C. F. W. Becker, *Chem. Soc. Rev.*, 2018, **47**, 9046–9068.
- 21 N. Ollivier, T. Toupy, R. C. Hartkoorn, R. Desmet, J. M. Monbaliu and O. Melnyk, *Nat. Commun.*, 2018, **9**, 2847.
- 22 R. Kleineweischede and C. P. R. Hackenberger, *Angew. Chem., Int. Ed.*, 2008, **47**, 5984–5988.
- 23 J. W. Bode, R. M. Fox and K. D. Baucom, *Angew. Chem., Int. Ed.*, 2006, **45**, 1248–1252.
- 24 T. Fukuzumi, L. Ju and J. W. Bode, *Org. Biomol. Chem.*, 2012, **10**, 5837–5844.
- 25 V. R. Pattabiraman, A. O. Ogunkoya and J. W. Bode, *Angew. Chem., Int. Ed.*, 2012, **51**, 5114–5118.
- 26 X. Li, H. Y. Lam, Y. Zhang and C. K. Chan, *Org. Lett.*, 2010, **12**, 1724–1727.
- 27 H. Y. Lam and X. Li, *Synlett*, 2014, 1339–1344.
- 28 C. L. Lee, H. Y. Lam and X. Li, *Nat. Prod. Rep.*, 2015, **32**, 1274–1279.
- 29 C. T. T. Wong, H. Y. Lam, T. Song, G. Chen and X. Li, *Angew. Chem., Int. Ed.*, 2013, **52**, 10212–10215.
- 30 C. Xu, J. Xu, H. Liu and X. Li, *Chin. Chem. Lett.*, 2018, **29**, 1119–1122.
- 31 I. Bosnjak, V. Bojovic, T. Segvic-Bubic and A. Bielen, *Protein Eng., Des. Sel.*, 2014, **27**, 65–72.
- 32 B. K. W. Chunga and A. K. Yudina, *Org. Biomol. Chem.*, 2015, **13**, 8768–8779.
- 33 Y. Zheng, L. Zhai, Y. Zhao and C. Wu, *J. Am. Chem. Soc.*, 2015, **137**, 15094–15097.
- 34 Y. Zheng, Z. Li, J. Ren, W. Liu, Y. Wu, Y. Zhao and C. Wu, *Chem. Sci.*, 2017, **8**, 2547–2552.
- 35 A. Taguchi, K. Kobayashi, Y. Cui, K. Takayama, A. Taniguchi and Y. Hayashi, *J. Org. Chem.*, 2020, **85**, 1495–1503.
- 36 H. Shida, A. Taguchi, S. Konno, K. Takayama, A. Taniguchi and Y. Hayashi, *Chem. Pharm. Bull.*, 2023, **71**, 435–440.
- 37 B. P. Sutherland, B. M. El-Zaatari, N. I. Halaszynski, J. M. French, S. Bai and C. J. Kloxin, *Bioconjugate Chem.*, 2018, **29**, 3987–3992.
- 38 R. Mousa, S. Lansky, G. Shoham and N. Metanis, *Chem. Sci.*, 2018, **9**, 4814–4820.
- 39 O. Koniev and A. Wagner, *Chem. Soc. Rev.*, 2015, **44**, 5495–5551.
- 40 F. M. Brunel and P. E. Dawson, *Chem. Commun.*, 2005, 2552–2554.
- 41 J. Li, W. Lai, A. Pang, L. Liu, L. Ye and X. Xiong, *Org. Lett.*, 2022, **24**, 1673–1677.
- 42 A. A. Aimetti, R. K. Shoemaker, C. C. Lin and K. S. Anseth, *Chem. Commun.*, 2010, **46**, 4061–4063.

43 Y. Tian, D. Yang, X. Ye and Z. Li, *Chem. Rec.*, 2017, **17**, 874–885.

44 Y. Tian, J. Li, H. Zhao, X. Zeng, D. Wang, Q. Liu, X. Niu, X. Huang, N. Xu and Z. Li, *Chem. Sci.*, 2016, **7**, 3325–3330.

45 A. J. Cameron, P. W. R. Harris and M. A. Brimble, *Angew. Chem., Int. Ed.*, 2020, **59**, 18054–18061.

46 L. R. Malins, J. N. Degruyter, K. J. Robbins, P. M. Scola, M. D. Eastgate, M. R. Ghadiri and P. S. Baran, *J. Am. Chem. Soc.*, 2017, **139**, 5233–5241.

47 V. Adebomi, R. D. Cohen, R. Wills, H. A. H. Chavers, G. E. Martin and M. Raj, *Angew. Chem., Int. Ed.*, 2019, **131**, 19249–19256.

48 A. Bandyopadhyay and J. Gao, *J. Am. Chem. Soc.*, 2016, **138**, 2098–2101.

49 B. Li, J. Parker, J. Tong and T. Kodadek, *J. Am. Chem. Soc.*, 2024, **146**, 14633–14644.

50 Y. Wang and D. H.-C. Chou, *Angew. Chem., Int. Ed.*, 2015, **54**, 10931–10934.

51 D. P. Fairlie and A. D. de Araujo, *Pept. Sci.*, 2016, **106**, 843–852.

52 Q. Zuo, Y. Li, X. Lai, G. Bao, L. Chen, Z. He, X. Song, R. E. P. Wang, Y. Shi, H. Luo, W. Sun and R. Wang, *Adv. Sci.*, 2024, 2308491.

53 E. V. Vinogradova, C. Zhang, A. M. Spokoiny, B. L. Pentelute and S. L. Buchwald, *Nature*, 2015, **526**, 687–691.

54 K. Kubota, P. Dai, B. L. Pentelute and S. L. Buchwald, *J. Am. Chem. Soc.*, 2018, **140**, 3128–3133.

55 X. Lin, O. Harel and M. Jbara, *Angew. Chem., Int. Ed.*, 2024, **63**, e202317511.

56 Y. Zhang, Q. Zhang, C. T. T. Wong and X. Li, *J. Am. Chem. Soc.*, 2019, **141**, 12274–12279.

57 M. Todorovic, K. D. Schwab, J. Zeisler, C. C. Zhang, F. Benard and D. M. Perrin, *Angew. Chem., Int. Ed.*, 2019, **58**, 14120–14124.

58 B. Li, H. Tang, A. Turluk, Z. Wan, X.-S. Xue, L. Li, X. Yang, J. Li, G. He, K. N. Houk and G. Chen, *Angew. Chem., Int. Ed.*, 2021, **60**, 6646–6652.

59 B. Li, L. Wang, X. Chen, X. Chu, H. Tang, J. Zhang, G. He, L. Li and G. Chen, *Nat. Commun.*, 2022, **13**, 311.

60 P. Guo, X. Chu, C. Wu, T. Qiao, W. Guan, C. Zhou, T. Wang, C. Tian, G. He and G. Chen, *Angew. Chem., Int. Ed.*, 2024, e202318893.

61 G. Bao, P. Wang, J. Li, X. Song, T. Yu, J. Zhang, Y. Li, Z. He, E. Ruiyao, X. Miao, J. Xie, J. Ni, R. Wang and W. Sun, *CCS Chem.*, 2023, 1547–1556.

62 Y. Zhang, R. Yin, H. Jiang, C. Wang, X. Wang, D. Wang, K. Zhang, R. Yu, X. Li and T. Jiang, *Org. Lett.*, 2023, **25**, 2248–2252.

63 J. E. Montgomery, J. A. Donnelly, S. W. Fanning, T. E. Speltz, X. H. Shangguan, J. S. Coukos, G. L. Greene and R. E. Moellering, *J. Am. Chem. Soc.*, 2019, **141**, 16374–16381.

64 Q. Luo, Y. Tao, W. Sheng, J. Lu and H. Wang, *Nat. Commun.*, 2019, **10**, 142.

65 Y. Wu, H. Chau, W. Thor, K. H. Y. Chan, X. Ma, W. Chan, N. Long and K. Wong, *Angew. Chem., Int. Ed.*, 2021, **133**, 20463–20469.

66 R. Hili, V. Rai and A. K. Yudin, *J. Am. Chem. Soc.*, 2010, **132**, 2889–2891.

67 A. V. Vasco, C. S. Pérez, F. E. Morales, H. E. Garay, D. Vasilev, J. A. Gavín, L. A. Wessjohann and D. G. Rivera, *J. Org. Chem.*, 2015, **80**, 6697–6707.

68 A. Doemling, M. Ricardo, A. Ali, J. Plewka, E. Surmiak, B. Labuzek, C. Neochoritis, J. Atmaj, L. Skalniak, R. Zhang, T. Holak, M. Groves and D. Rivera, *Angew. Chem., Int. Ed.*, 2020, **59**, 5235–5241.

69 A. Yamaguchi, S. J. Kaldas, S. D. Appavoo, D. B. Diaz and A. K. Yudin, *Chem. Commun.*, 2019, **55**, 10567–10570.

70 S. Krajcovicova and D. R. Spring, *Angew. Chem., Int. Ed.*, 2023, **62**, e202307782.

71 J. R. Frost, C. C. G. Scully and A. K. Yudin, *Nat. Chem.*, 2016, **8**, 1105–1111.

72 T. Liu, S. Xu and J. Zhao, *Chin. J. Org. Chem.*, 2021, **41**, 873–887.

73 J. Yang, C. Wang, S. Xu and J. Zhao, *Angew. Chem., Int. Ed.*, 2019, **58**, 1382–1386.

74 S. Xu, D. Jiang, Z. Peng, L. Hu, T. Liu, L. Zhao and J. Zhao, *Angew. Chem., Int. Ed.*, 2022, **61**, e202212247.

75 P. Botti, T. D. Pallin and J. P. Tam, *J. Am. Chem. Soc.*, 1996, **118**, 10018–10024.

76 H. Chen and Q. Zhang, *J. Am. Chem. Soc.*, 2023, **145**, 27218–27224.

77 E. Fowler and J. Kim, *Chem*, 2024, **10**, 730–745.

78 O. Nwajiobi, A. K. Verma and M. Raj, *J. Am. Chem. Soc.*, 2022, **144**, 4633–4641.

79 H. C. Kolb, M. G. Finn and K. B. Sharpless, *Angew. Chem., Int. Ed.*, 2001, **40**, 2004–2021.

80 C. W. Tornøe, C. Christensen and M. Meldal, *J. Org. Chem.*, 2002, **67**, 3057–3064.

81 Y. Angell and K. Burgess, *J. Org. Chem.*, 2005, **70**, 9595–9598.

82 M. Strack, É. Billard, D. Chatenet and W. D. Lubell, *Bioorg. Med. Chem. Lett.*, 2017, **27**, 3412–3416.

83 K. Holland-Nell and M. Meldal, *Angew. Chem., Int. Ed.*, 2011, **50**, 5204–5206.

84 Y. H. Lau, P. de Andrade, S.-T. Quah, M. Rossmann, L. Laraia, N. Skold, T. J. Sum, P. J. E. Rowling, T. L. Joseph, C. Verma, M. Hyvonen, L. S. Itzhaki, A. R. Venkitaraman, C. J. Brown, D. P. Lane and D. R. Spring, *Chem. Sci.*, 2014, **5**, 1804–1809.

85 T. P. Thu, C. O. Larsen, T. Rondbjerg, M. De Foresta, M. B. A. Kunze, A. Marek, J. H. Loper, L.-E. Boyhus, A. Knuhtsen, K. Lindorff-Larsen and D. S. Pedersen, *Chem. – Eur. J.*, 2017, **23**, 3490–3495.

86 S. Li, H. Cai, J. He, H. Chen, S. Lam, T. Cai, Z. Zhu, S. J. Bark and C. Cai, *Bioconjugate Chem.*, 2016, **27**, 2315–2322.

87 Y. Wang and Q. Hu, *Adv. NanoBiomed. Res.*, 2023, **3**, 2200128.

88 Y. H. Lau, Y. Wu, M. Rossmann, B. X. Tan, P. de Andrade, Y. S. Tan, C. Verma, G. J. McKenzie, A. R. Venkitaraman,

M. Hyvonen and D. R. Spring, *Angew. Chem., Int. Ed.*, 2015, **54**, 15410–15413.

89 D. Astruc, *New J. Chem.*, 2005, **29**, 42–56.

90 C. E. Schafmeister, J. Po and G. L. Verdine, *J. Am. Chem. Soc.*, 2000, **122**, 5891–5892.

91 E. C. Gleeson, W. R. Jackson and A. J. Robinson, *Tetrahedron Lett.*, 2016, **57**, 4325–4333.

92 X. Lu, L. Fan, C. B. Phelps, C. P. Davie and C. P. Donahue, *Bioconjugate Chem.*, 2017, **28**, 1625–1629.

93 S. Masuda, S. Tsuda and T. Yoshiya, *Org. Biomol. Chem.*, 2018, **16**, 9364–9367.

94 A. H. Hoveyda and A. R. Zhugralin, *Nature*, 2007, **450**, 243–251.

95 N. Ghalit, A. J. Poot, A. Fürstner, D. T. S. Rijkers and R. M. J. Liskamp, *Org. Lett.*, 2005, **7**, 2961–2964.

96 P. M. Cromm, S. Schaubach, J. Spiegel, A. Fürstner, T. N. Grossmann and H. Waldmann, *Nat. Commun.*, 2016, **7**, 11300.

97 B. Chen, C. Liu, W. Cong, F. Gao, Y. Zou, L. Su, L. Liu, A. Hillisch, L. Lehmann, D. Bierer, X. Li and H. Hu, *Chem. Sci.*, 2023, **14**, 11499–11506.

98 L. Chu, C. Ohta, Z. Zuo and D. W. C. MacMillan, *J. Am. Chem. Soc.*, 2014, **136**, 10886–10889.

99 S. J. McCarver, J. Qiao, J. Carpenter, R. M. Borzilleri, M. A. Poss, M. D. Eastgate, M. M. Miller and D. W. C. MacMillan, *Angew. Chem., Int. Ed.*, 2017, **56**, 728–732.

100 T. Qin, L. R. Malins, J. T. Edwards, R. R. Merchant, A. J. E. Novak, J. Zhong, R. B. Mills, M. Yan, C. Yuan, M. D. Eastgate and P. S. Baran, *Angew. Chem., Int. Ed.*, 2017, **56**, 260–265.

101 H. Lee, N. C. Boyer, Q. Deng, H. Y. Kim, T. K. Sawyer and N. Sciammenta, *Chem. Sci.*, 2019, **10**, 5073–5078.

102 J. A. Terrett, J. D. Cuthbertson, V. W. Shurtleff and D. W. C. MacMillan, *Nature*, 2015, **524**, 330–334.

103 X. Hu, X. Chen, B. Li, G. He and G. Chen, *Org. Lett.*, 2021, **23**, 716–721.

104 A. Benny and E. M. Scanlan, *Chem. Commun.*, 2024, **60**, 7950–7953.

105 H. Gruß and N. Sewald, *Chem. Eur. J.*, 2020, **26**, 5328–5340.

106 W. Wang, M. Lorion, J. Shah, A. R. Kapdi and L. Ackermann, *Angew. Chem., Int. Ed.*, 2018, **57**, 14700–14717.

107 J. Ruiz-Rodríguez, F. Albericio and R. Lavilla, *Chem. – Eur. J.*, 2010, **16**, 1124–1127.

108 H. Dong, C. Limberakis, S. Liras, D. Priceb and K. James, *Chem. Commun.*, 2012, **48**, 11644–11646.

109 L. Mendive-Tapia, S. Preciado, J. García, R. Ramon, N. Kielland, F. Albericio and R. Lavilla, *Nat. Commun.*, 2015, **6**, 7160.

110 Z. Bai, C. Cai, Z. Yu and H. Wang, *Angew. Chem., Int. Ed.*, 2018, **130**, 14108–14112.

111 J. Tan, J. Wu, S. Liu, H. Yao and H. Wang, *Sci. Adv.*, 2019, **5**, eaaw0323.

112 J. Tang, H. Chen, Y. He, W. Sheng, Q. Bai and H. Wang, *Nat. Commun.*, 2018, **9**, 3383.

113 Z. Bai, C. Cai, W. Sheng, Y. Ren and H. Wang, *Angew. Chem., Int. Ed.*, 2020, **59**, 14686–14692.

114 S. Liu, Ch Cai, Z. Bai, W. Sheng, J. Tan and H. Wang, *Org. Lett.*, 2021, **23**, 2933–2937.

115 B. Han, B. Li, L. Qi, P. Yang, G. He and G. Chen, *Org. Lett.*, 2020, **22**, 6879–6883.

116 W. Gong, G. Zhang, T. Liu, R. Giri and J. Yu, *J. Am. Chem. Soc.*, 2014, **136**, 16940–16946.

117 A. F. M. Noisier, J. Garc, I. A. Ionut and F. Albericio, *Angew. Chem., Int. Ed.*, 2016, **128**, 314–318.

118 J. Tang, Y. He, H. Chen, W. Sheng and H. Wang, *Chem. Sci.*, 2017, **8**, 4565–4570.

119 X. Zhang, G. Lu, M. Sun, M. Mahankali, Y. Ma, M. Zhang, W. Hua, Y. Hu, Q. Wang, J. Chen, G. He, X. Qi, W. Shen, P. Liu and G. Chen, *Nat. Chem.*, 2018, **10**, 540–548.

120 Z. Ruan, N. Sauermann, E. Manoni and L. Ackermann, *Angew. Chem., Int. Ed.*, 2017, **129**, 3172–3176.

121 N. Kaplaneris, T. Rogge, R. Yin, H. Wang, G. Sirvinskaite and L. Ackermann, *Angew. Chem., Int. Ed.*, 2019, **58**, 3476–3480.

122 N. Kaplaneris, F. Kaltenhauser, G. Sirvinskaite, S. Fan, T. De Oliveira, L. C. Conradi and L. Ackermann, *Sci. Adv.*, 2021, **7**, eabe6202.

123 P. Wang, J. Liu, X. Zhu, Kenry, Z. Yan, J. Yan, J. Jiang, M. Fu, J. Ge, Q. Zhu and Y. Zheng, *Nat. Commun.*, 2023, **14**, 3973.

124 S. Shabani and C. A. Hutton, *Org. Lett.*, 2020, **22**, 4557–4561.

125 K. V. Lawson, T. E. Rose and P. G. Harran, *Proc. Natl. Acad. Sci. U. S. A.*, 2013, **110**, E3753–E3760.

126 Z. Chang, S. Wang, J. Huang, G. Chen, Z. Tang, R. Wang and D. Zhao, *Sci. Adv.*, 2023, **9**, eadj3090.

127 P. Yang, X. Wang, B. Li, Y. Yang, J. Yue, Y. Suo, H. Tong, G. He, X. Lu and G. Chen, *Chem. Sci.*, 2021, **12**, 5804–5810.

128 K. Fukumoto, M. Yazaki and M. Arisawa, *Org. Lett.*, 2024, **26**, 221–224.

129 P. Yang, M. J. Širvinskas, B. Li, N. W. Heller, H. Rong, G. He, A. K. Yudin and G. Chen, *J. Am. Chem. Soc.*, 2023, **145**, 13968–13978.

130 W. Li, Y. Chen, Y. Chen, S. Xia, W. Chang, Ch Zhu, K. N. Houk, Y. Liang and J. Xie, *J. Am. Chem. Soc.*, 2023, **145**, 14865–14873.

131 Y. Liu, G. Li, W. Ma, G. Bao, Y. Li, Z. He, Z. Xu, R. Wang and W. Sun, *Chem. Sci.*, 2024, **15**, 11099–11107.

132 D. Liu, G. M. Rubin, D. Dhakal, M. Chen and Y. Ding, *iScience*, 2021, **24**, 102512.

133 J. Lu, Y. Wu, Y. Li and H. Wang, *Angew. Chem., Int. Ed.*, 2021, **60**, 1951–1958.

134 D. T. Nguyen, T. T. Le, A. J. Rice, G. A. Hudson, W. A. van der Donk and D. A. Mitchell, *J. Am. Chem. Soc.*, 2022, **144**, 11263–11269.

135 N. Bionda, A. L. Cryan and R. Fasan, *ACS Chem. Biol.*, 2014, **9**, 2008–2013.

136 J. Lu, Y. Li, Z. Bai, H. Lv and H. Wang, *Nat. Prod. Rep.*, 2021, **38**, 981–992.



137 Z. L. Budimir, R. S. Patel, A. Eggly, C. N. Evans, H. M. Rondon-Cordero, J. J. Adams, C. Das and E. I. Parkinson, *Nat. Chem. Biol.*, 2024, **20**, 120–128.

138 M. L. Adrover-Castellano, J. J. Schmidt and D. H. Sherman, *ChemCatChem*, 2021, **13**, 2095–2116.

139 M. Kobayashi, K. Fujita, K. Matsuda and T. Wakimoto, *J. Am. Chem. Soc.*, 2023, **145**, 3270–3275.

140 T. Kawakami, A. Ohta, M. Ohuchi, H. Ashigai, H. Murakami and H. Suga, *Nat. Chem. Biol.*, 2009, **5**, 888–890.

141 T. Kawakami and S. Aimoto, *Chem. Lett.*, 2007, **36**, 76–77.

142 M. Spinck, C. Piedrafita, W. E. Robertson, T. S. Elliott, D. Cervettini, D. de la Torre and J. W. Chin, *Nat. Chem.*, 2023, **15**, 61–69.

143 V. Baeriswyl and C. Heinis, *ChemMedChem*, 2013, **8**, 377–384.

144 D. Feng, L. Liu, Y. Shi, P. Du, S. Xu, Z. Zhu, J. Xu and H. Yao, *Chin. Chem. Lett.*, 2023, **34**, 108026.

145 A. M. Jaulent and R. J. Leatherbarrow, *Protein Eng., Des. Sel.*, 2004, **17**, 681–687.

146 J. Luo, Y. Gao, R. Zhao, J. Shi and Y. Li, *Org. Biomol. Chem.*, 2023, **21**, 8863–8867.

147 S. Dengler, C. Douat and I. Huc, *Angew. Chem., Int. Ed.*, 2022, **61**, e202211138.

148 B. Li, Z. Wan, H. Zheng, S. Cai, H. Tian, H. Tang, X. Chu, G. He, D. Guo, X. Xue and G. Chen, *J. Am. Chem. Soc.*, 2022, **144**, 10080–10090.

149 A. V. Vasco, Y. Méndez, C. González, C. S. Pérez, L. Reguera, L. A. Wessjohann and D. G. Rivera, *ChemBioChem*, 2023, **24**, e202300229.

150 D. S. Kemp and P. E. McNamara, *J. Org. Chem.*, 1985, **50**, 5834–5838.

151 P. Timmerman, J. Beld, W. C. Puijk and R. H. Meloen, *ChemBioChem*, 2005, **6**, 821–824.

152 C. Heinis, T. Rutherford, S. Freund and G. Winter, *Nat. Chem. Biol.*, 2009, **5**, 502–507.

153 S. Chen, J. Morales-Sanfrutos, A. Angelini, B. Cutting and C. Heinis, *ChemBioChem*, 2012, **13**, 1032–1038.

154 K. Deyle, X. Kong and C. Heinis, *Acc. Chem. Res.*, 2017, **50**, 1866–1874.

155 C. Ernst, J. Heidrich, C. Sessler, J. Sindlinger, D. Schwarzer, P. Koch and F. M. Boeckler, *Front. Chem.*, 2018, **6**, 484.

156 Q. Yu, L. Bai and X. Jiang, *Angew. Chem., Int. Ed.*, 2023, **62**, e202314379.

157 C. Zhang, E. V. Vinogradova, A. M. Spokoyny, S. L. Buchwald and B. L. Pentelute, *Angew. Chem., Int. Ed.*, 2019, **58**, 4810–4839.

158 A. M. Spokoyny, Y. Zou, J. J. Ling, H. Yu, Y.-S. Lin and B. L. Pentelute, *J. Am. Chem. Soc.*, 2013, **135**, 5946–5949.

159 W. Liu, Y. Zheng, X. Kong, C. Heinis, Y. Zhao and C. Wu, *Angew. Chem., Int. Ed.*, 2017, **56**, 4458–4463.

160 J. Wang, M. Zha, Q. Fei, W. Liu, Y. Zhao and C. Wu, *Chem. – Eur. J.*, 2017, **23**, 15150–15155.

161 J. M. Wolfe, C. M. Fadzen, R. L. Holden, M. Yao, G. J. Hanson and B. L. Pentelute, *Angew. Chem., Int. Ed.*, 2018, **57**, 4756–4759.

162 P. Dognini, T. Chaudhry, G. Scagnetti, M. Assante, G. S. M. Hanson, K. Ross, F. Giuntini and C. R. Coxon, *Chem. – Eur. J.*, 2023, **29**, e202301410.

163 M. Wang, D. Pan, Q. Zhang, Y. Lei, C. Wang, H. Jia, L. Mou, X. Miao, X. Ren and Z. Xu, *J. Am. Chem. Soc.*, 2024, **146**, 6675–6685.

164 X. Chu, L. Shen, B. Li, P. Yang, C. Du, X. Wang, G. He, S. Messaoudi and G. Chen, *Org. Lett.*, 2021, **23**, 8001–8006.

165 J. M. Stauber, A. L. Rheingold and A. M. Spokoyny, *Inorg. Chem.*, 2021, **60**, 5054–5062.

166 G. E. Mudd, S. J. Stanway, D. R. Witty, A. Thomas, S. Baldo, A. D. Bond, P. Beswick and A. Highton, *Bioconjugate Chem.*, 2022, **33**, 1441–1445.

167 M. Matzapetakis, D. Ghosh, T. Weng, J. E. Penner-Hahn and V. L. Pecoraro, *J. Biol. Inorg. Chem.*, 2006, **11**, 876–890.

168 C. Nitsche, M. C. Mahawaththha, W. Becker, T. Huber and G. Otting, *Chem. Commun.*, 2017, **53**, 10894–10897.

169 S. Voss, J. Rademann and C. Nitsche, *Angew. Chem., Int. Ed.*, 2022, **61**, e202113857.

170 S. Voss, L. Adair, K. Achazi, H. Kim, S. Bergemann, R. Bartenschlager, E. New, J. Rademann and C. Nitsche, *Angew. Chem., Int. Ed.*, 2023, **63**, e202318615.

171 M. R. Jafari, H. Yu, J. M. Wickware, Y. Lin and R. Derda, *Org. Biomol. Chem.*, 2018, **16**, 7588–7594.

172 G. Richelle, M. Schmidt, H. Ippel, T. Hackeng, J. van Maarseveen, T. Nuijens and P. Timmerman, *ChemBioChem*, 2018, **19**, 1934–1938.

173 D. E. Streefkerk, M. Schmidt, J. H. Ippel, T. M. Hackeng, T. Nuijens, P. Timmerman and J. H. van Maarseveen, *Org. Lett.*, 2019, **21**, 2095–2100.

174 F. Chen, N. Pinnette, F. Yang and J. Gao, *Angew. Chem., Int. Ed.*, 2023, **62**, e202306813.

175 R. M. Reja, B. Chau and J. Gao, *Org. Lett.*, 2023, **25**, 4489–4492.

176 S. Ullrich, J. George, A. E. Coram, R. Morewood and C. Nitsche, *Angew. Chem., Int. Ed.*, 2022, **61**, e202208400.

177 X. Liu, O. Mykhailenko, A. Faraone and J. Waser, *Angew. Chem., Int. Ed.*, 2024, e202404747.

178 X. Wang, X. Bao, M. McFarland-Mancini, I. Isaacsohn, A. F. Drew and D. B. Smithrud, *J. Am. Chem. Soc.*, 2007, **129**, 7284–7293.

179 S. Erbas-Cakmak, D. A. Leigh, C. T. McTernan and A. L. Nussbaumer, *Chem. Rev.*, 2015, **115**, 10081–10206.

180 A. W. Heard, J. M. Suárez and S. M. Goldup, *Nat. Rev. Chem.*, 2022, **6**, 182–196.

181 N. Pairault, R. Barat, I. Tranoy-Opalinski, B. Renoux, M. Thomas and S. Papot, *C. R. Chimie*, 2016, **19**, 103–112.

182 M. O. Maksimov, S. Pan and A. J. Link, *Nat. Prod. Rep.*, 2012, **29**, 996–1006.

183 N. C. H. Lim and S. E. Jackson, *J. Phys.: Condens. Matter*, 2015, **27**, 354101.

184 W. Clegg, C. Gimenez-Saiz, D. A. Leigh, A. Murphy, A. M. Z. Slawin and S. J. Teat, *J. Am. Chem. Soc.*, 1999, **121**, 4124–4129.



185 M. Asakawa, G. Brancato, M. Fanti, D. A. Leigh, T. Shimizu, A. M. Z. Slawin, J. K. Y. Wong, F. Zerbetto and S. Zhang, *J. Am. Chem. Soc.*, 2002, **9**, 2939–2950.

186 H. Onagi and J. Rebek, Jr, *Chem. Commun.*, 2005, 4604–4606.

187 A. Moretto, I. Menegazzo, M. Crisma, E. J. Shotton, H. Nowell, S. Mammi and C. Toniolo, *Angew. Chem., Int. Ed.*, 2009, **48**, 8986–8989.

188 A. Fernandes, A. Viterisi, F. Coutrot, S. Potok, D. A. Leigh, V. Aucagne and S. Papot, *Angew. Chem., Int. Ed.*, 2009, **121**, 6565–6569.

189 V. Aucagne, D. A. Leigh, J. S. Lock and A. R. Thomson, *J. Am. Chem. Soc.*, 2006, **128**, 1784–1785.

190 J. W. Blankenship and P. E. Dawson, *Protein Sci.*, 2007, **16**, 1249–1256.

191 S. Pilon, S. I. Jørgensen and J. H. van Maarseveen, *ACS Org. Inorg. Au.*, 2021, **1**, 37–42.

192 T. Kurita, M. Higashi, J. Gimenez-Dejoz, S. Fujita, H. Uji, H. Sato and K. Numata, *Biomacromolecules*, 2024, **25**, 3661–3670.

193 T. Liu, X. Ma, J. Yu, W. Yang, G. Wang, Z. Wang, Y. Ge, J. Song, H. Han, W. Zhang, D. Yang, X. Liu and M. Ma, *Chem. Sci.*, 2021, **12**, 12353–12364.

194 L. Zhang, P. Wang, X. Zhou, L. Bretin, X. Zeng, Y. Husiev, E. A. Polanco, G. Zhao, L. S. Wijaya, T. Biver, S. E. Le Dévédec, W. Sun and S. Bonnet, *J. Am. Chem. Soc.*, 2023, **145**, 14963–14980.

195 E. Cupioli, F. J. M. Gaigne, A. Sachse, P. Buday, W. Weigand, P. Liebing and H. D. Arndt, *Angew. Chem., Int. Ed.*, 2023, **62**, e202304901.

196 C. D. Allen and A. J. Link, *J. Am. Chem. Soc.*, 2016, **138**, 14214–14217.

197 H. V. Schröder, Y. Zhang and A. J. Link, *Nat. Chem.*, 2021, **13**, 850–857.

198 X. Ma, J. Jia, R. Cao, X. Wang and H. Fei, *J. Am. Chem. Soc.*, 2014, **136**, 17734–17737.

199 T. Sawada, A. Matsumoto and M. Fujita, *Chem*, 2014, **126**, 7356–7360.

200 T. Sawada and M. Fujita, *Chem*, 2020, **6**, 1861–1876.

201 L. Ferrazzano, M. Catani, A. Cavazzini, G. Martelli, D. Corbisiero, P. Cantelmi, T. Fantoni, A. Mattellone, C. De Luca, S. Felletti, W. Cabri and A. Tolomelli, *Green Chem.*, 2022, **24**, 975–1020.

202 J. M. Palomo, *RSC Adv.*, 2014, **4**, 32658–32672.

203 S. Ingale and P. E. Dawson, *Org. Lett.*, 2011, **13**, 2822–2825.

204 P. A. Cistrone, A. P. Silvestri, J. C. J. Hintzen and P. E. Dawson, *ChemBioChem*, 2018, **19**, 1031–1035.

205 H. Asfaw, T. Wetzlär, M. S. Martinez-Martinez and P. Imming, *Bioorg. Med. Chem. Lett.*, 2018, **28**, 2899–2905.

206 D. B. Diaz, S. D. Appavoo, A. F. Bogdanchikova, Y. Lebedev, T. J. McTiernan, G. D. P. Gomes and A. K. Yudin, *Nat. Chem.*, 2021, **13**, 218–225.

207 Q. Nhu, N. Nguyen, J. Schwochert, D. J. Tantillo and R. S. Lokey, *Phys. Chem. Chem. Phys.*, 2018, **20**, 14003–14012.

208 P. Hosseinzadeh, G. Bhardwaj, V. K. Mulligan, M. D. Shortridge, T. W. Craven, F. Pardo-Avila, S. A. Rettie, D. E. Kim, D.-A. Silva, Y. M. Ibrahim, I. K. Webb, J. R. Cort, J. N. Adkins, G. Varani and D. Baker, *Science*, 2017, **358**, 1461–1466.

209 J. Miao, M. L. Descoteaux and Y. Lin, *Chem. Sci.*, 2021, **12**, 14927–14936.

210 S. A. Rettie, K. V. Campbell, A. K. Bera, A. Kang, S. Kozlov, J. De La Cruz, V. Adebomi, G. Zhou, F. DiMaio, S. Ovchinnikov and G. Bhardwaj, *bioRxiv*, 2023, 529956.

211 R. Thakkar, D. Upreti, S. Ishiguro, M. Tamura and J. Comer, *RSC Med. Chem.*, 2023, **14**, 658–670.

212 A. Ohta, M. Tanada, S. Shinohara, Y. Morita, K. Nakano, Y. Yamagishi, R. Takano, S. Kariyuki, T. Iida, A. Matsuo, K. Ozeki, T. Emura, Y. Sakurai, K. Takano, A. Higashida, M. Kojima, T. Muraoka, R. Takeyama, T. Kato, K. Kimura, K. Ogawa, K. Ohara, S. Tanaka, Y. Kikuchi, N. Hisada, R. Hayashi, Y. Nishimura, K. Nomura, T. Tachibana, M. Irie, H. Kawada, T. Torizawa, N. Murao, T. Kotake, M. Tanaka, S. Ishikawa, T. Miyake, M. Tamiya, M. Arai, A. Chiyoda, S. Akai, H. Sase, S. Kuramoto, T. Ito, T. Shiraishi, T. Kojima and H. Iikura, *J. Am. Chem. Soc.*, 2023, **145**, 24035–24051.

213 Q. Song, Z. Cheng, M. Kariuki, S. C. L. Hall, S. K. Hill, J. Y. Rho and S. Perrier, *Chem. Rev.*, 2021, **121**, 13936–13995.

214 H. C. Hayes, L. Y. P. Luk and Y. H. Tsai, *Org. Biomol. Chem.*, 2021, **19**, 3983–4001.

215 M. E. Hansen, S. O. Yasmin, S. Wolfrum and E. M. Carreira, *Angew. Chem., Int. Ed.*, 2022, **61**, e202203051.

216 M. Todorovic, A. Blanc, Z. Wang, J. Lozada, J. Froelich, J. Zeisler, C. Zhang, H. Merkens, F. Benard and D. M. Perrin, *Chem. – Eur. J.*, 2024, **30**, e202304270.

217 S. J. Cantrill, R. H. Grubbs, D. Lanari, K. C.-F. Leung, A. Nelson, K. G. Poulin-Kerstien, S. P. Smidt, J. F. Stoddart and D. A. Tirrell, *Org. Lett.*, 2005, **7**, 4213–4216.

218 H. Hou, K. C.-F. Leung, D. Lanari, A. Nelson, J. F. Stoddart and R. H. Grubbs, *J. Am. Chem. Soc.*, 2006, **128**, 15358–15359.

219 C.-S. Kwan, R. Zhao, M. A. Van Hove, Z. Cai and K. C.-F. Leung, *Nat. Commun.*, 2018, **9**, 497.

220 D. N. Tritton, F.-K. Tang, G. B. Bodedla, F.-W. Lee, C.-S. Kwan, K. C.-F. Leung, X. Zhu and W.-Y. Wong, *Coord. Chem. Rev.*, 2022, **459**, 214390.

221 W.-L. Chan, C. Xie, W.-S. Lo, J.-C. G. Bünzli, W.-K. Wong and K.-L. Wong, *Chem. Soc. Rev.*, 2021, **50**, 12189–12257.

222 C. J. White and A. K. Yudin, *Nat. Chem.*, 2011, **3**, 509–524.

